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ABSTRACT
Asukamycin, a member of the manumycin family metabolites, is an antimicrobial and
potential antitumor agent isolated from Streptomyces nodosus subsp. asukaensis. The entire
asukamycin biosynthetic gene cluster was cloned, assembled and expressed heterologously in
Streptomyces lividans. Bioinformatic analysis and mutagenesis studies elucidated the
biosynthetic pathway at the genetic and biochemical level. Four gene sets, asuA-D, govern the
formation and assembly of the asukamycin building blocks, a 3-amino-4-hydroxybenzoic acid
(3,4-AHBA) core component, a cyclohexane ring, two triene polyketide chains and a 2-amino-3hydroxycyclopent-2-enone (C5N) moiety to form the intermediate protoasukamycin. AsuE1 and
AsuE2 catalyze the conversion of protoasukamycin to 4-hydroxyprotoasukamycin, which is
epoxidized at C5-C6 by AsuE3 to the final product, asukamycin. Branched acyl CoA starter
units, derived from Val, Leu and Ile, can be incorporated by the actions of the polyketide
synthase KSIII AsuC3/C4 as well as the cellular fatty acid synthase FabH to produce the
asukamycin congeners A2-A7. In addition, the type II thioesterase AsuC15 limits the cellular
level of ω-cyclohexyl fatty acids and likely maintains homeostasis of the cellular membrane.
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CHAPTER ONE:

GENERAL INTRODUCTION
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Discovery of Manumycin Metabolites
The manumycin family of metabolites contains 34 members, and continues to expand due
to the ongoing discovery of novel natural products. The first member, manumycin A, was
isolated from Streptomyces parvulus Tü64 in 1963 [1]. Revealed by Zeeck group, the chemical
structure of manumycin A features two polyketide chains (Fig. 1.1) [2]. The “lower” trans triene
chain starts with a 2-amino-4-hydroxy-5,6-epoxycyclohex-2-enone (mC7N) core and terminates
into a five-membered ring, 2-amino-3-hydroxycyclopent-2-enone (C5N) moiety; the “upper” one
consists of methyl branched polyketide, amide-linked to the mC7N core. The stereochemistry of
this compound was first presented by Thiericke group [3, 4], and later revised by Taylor and coworkers [5].
Asukamycin (A1) was discovered in the fermentation culture of Streptomyces nodosus
subsp. asukaensis by Omura et al. in 1976 (Fig. 1.1) [6]. Elucidated by Omura and Floss groups,
asukamycin shares the entire lower chain with manumycin A, while it differs at the upper one, a
trans triene polyketide initiated with a characteristic cyclohexane moiety [7, 8]. Soon after the
discovery of asukamycin, twenty-one novel manumycin compounds including the type II form of
colabomycin D and manumycin D were subsequently identified during 1980s and 1990s (Table
1). These type II manumycins contain a hydroxyethylene group to replace the epoxy moiety at
the C5-C6 position of the mC7N core. Scrutinizing the metabolic profile of S. nodosus, Floss and
colleagues have identified six more asukamycin congeners, manumycin G (A2), El-1511-5 (A3),
U-56,407 (A4), manumycin E (A5), asukamycin F (A6), asukamycin G (A7), plus five type II
asukamycins, B1-B5 (Fig. 1.1) [6, 9, 10]. In the same study, a series of unnatural asukamycin
analogs, containing various cyclic ring structures to substitute the cyclohexane moiety were
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obtained through the feeding experiments with the variable ring-sized alicyclic carboxylates in S.
nodosus (Table 1).

Figure 1.1 Molecular structure of manumycin A, asukamycin, and congeners. Type I and II
metabolites are grouped according to the main core units of A and B, respectively.
3

Table 1.1 Structures of manumycin family metabolites.
Compounds
Type Ia

Stereochemistry

Manumycin A

4S, 5R, 6S*

[2-4, 11, 12]

Manumycin B

4S, 5R, 6S*

[11-14]

Manumycin C

4S, 5R, 6S

[11-14]

EI-1625-2

4S, 5R, 6S*

[14-17]

Compound

not determined

Asukamycin
(A1)

4S, 5R, 6S

[6-8, 10, 1921]

Manumycin E
(A5)

4S, 5 and 6 not
determined

[10, 22, 23]

Manumycin F

4S, 5 and 6 not
determined

[22, 23]

Manumycin G
(A2)

4S, 5 and 6 not
determined

[10, 17, 22, 23]

U-56, 407 (A4)

4S, 5R, 6S

[10, 24, 25]

EI-1511-5 (A3)

4S, 5R, 6S

[10, 14-17]

Possibly 4S, 5R, 6S

[10]

Possibly 4S, 5R, 6S

[10]

Possibly 4S, 5R, 6S

[10]

Possibly 4S, 5R, 6S

[10]

Possibly 4S, 5R, 6S

[10]

Cycloheptylasukamycin

Possibly 4S, 5R, 6S

[10]

Alisamycin

4R, 5S, 6R

[26-29]

Asukamycin F
(A6)
Asukamycin G
(A7)
Cyclopropylasukamycin
Cyclobutylasukamycin
Cyclopentylasukamycin

R1

R2

References

-OH
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[18]

table continued
Ent-alisamycin

4S, 5R, 6S

[14-17]

EI-1511-3

4S, 5R, 6S

[14-17]

Nisamycin

4R, 5S, 6R

-OH

[30-33]

Type Ib
Colabomycin A

4S, 5R, 6S

[34-36]

Type Ic
U-62, 162

not determined

-OH

[37]

Type IIa
Manumycin D

4S, 5R

[11, 13]

TMC-1A

4S, 5R

[11]

TMC-1B

4S, 5R

[11]

TMC-1C

4S, 5R

[11]

TMC-1D

4S, 5R

[11]

Asukamycin A-II
Possibly 4S, 5R
(B1)

[9]

Asukamycin B-II
Possibly 4S, 5R
(B2)

[9]

Asukamycin C-II
Possibly 4S, 5R
(B3)
Asukamycin D-II
Possibly 4S, 5R
(B4)
Asukamycin E-II
Possibly 4S, 5R
(B5)

[9]
[9]
[9]

Type IIb
Colabomycin D

4S, 5R

[36]
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Structure and Classification
Manumycin metabolites were categorized into two classes based on the structure of the
mC7N core moiety (Fig. 1.2). While the type I manumycins contain an oxirane at the C5-C6
position, a ring-opened hydroxyethylene was adopted by the type II compounds, which are likely
originated from their type I counterparts through an enzymatic /or non-enzymatic path (Fig. 1.2).
For example, the crude extract of asukamycin (A1) can be gradually reduced to the asukamycin
A-II (B1) under room temperature. To the type I form of manumycins, the mC7N core mostly
displays a 4S, 5R, 6S stereochemistry except for nisamycin and alisamycin, exhibiting a 4R, 5S,
6R configuration. Notably, the mC7N configuration was incorrectly assigned as a 4R, 5R, 6S for
manumycin A, manumycin B and EI-1625-2 in an early study. As manumycin A revealed an
opposite pattern of the optical rotation and CD spectrum compared with that of the synthesized
ent-(+)- manumycin A, the chirality of manumycin A has been revised to 4S, 5R, 6S. In this
study, we have identified two new classes besides type I and II manumycins, the proto-type (C1C5) and the 4-hydroxyproto-type (D1-D5), featuring with an aromatic and a hydroxyquinol
cores, respectively (see chapter 6).
Based on the chain length and the degree of saturation of the lower polyketide chain, the
type I manumycins are further divided into three subgroups. Type Ia, Ib, and Ic feature the
corresponding trans triene, tetraene, and saturated polyketides. The majority of manumycin
compounds belong to the type Ia subfamily, while colabomycin A and U-62,162 are the only
reported type Ib and Ic manumycins, respectively. Correspondingly, a majority of the type II
manumycins belong to the type IIa subgroup with one exception of the unique IIb member,
colabomycin D. Besides, most manumycins contain a lower polyketide chain amide-linked with
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a C5N moiety except for nisamycin and U-62,162, carrying a free carboxylic group without the
C5N moiety attached.

Figure 1.2 Classification of manumycins. The proto-type and the pre-type compounds are
discussed in chapter 6.
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Biological Activity
Antimicrobial Activity
Manumycin metabolites have been identified mostly through the antibiotic screening
based on their broad antimicrobial actions including the antibacterial (Gram-positive),
anticoccidial, and antifungal activities [38]. Manumycin A also exhibits the insecticidal activity
[39]. Although the detailed mechanism has yet been fully understood, the epoxyquinol moiety of
the mC7N core likely plays an essential role for these antimicrobial activity, as the type II
manumycins, TMC-1A-D and manumycin D, failed to show the effectiveness against the Grampositive or Gram-negative bacteria [11]. Interestingly, nisamycin, lacking a C5N moiety,
displayed 6-fold higher antibacterial potency than its C5N-containing analog, alisamycin. This
observation indicated that the presence of the C5N moiety might not be critical in view of the
biological activity [33]. Furthermore, the derivatives of nisamycin with an amide-linkage to an
alkane, a cycloalkane, or an arene also reduced its antimicrobial activity.
Anticancer Activity
Manumycin compounds are known for the anticancer function against various tumors in
vitro and in vivo [38]. Manumycin A has been proved to inhibit the progression of the human
fibrosarcoma HT1080 tumor cells in the transplanted mice [40]. Two other studies showed that
the human pancreatic cancer was significantly suppressed in vivo by the manumycin A treatment
without having apparent hepatotoxicity [41, 42]. In addition, manumycin A also displayed the
antiangiogenesis ability in mice transplanted with the hypoxic Anaplastic thyroid cancer (ATC)
cells, likely by limiting the vascular endothelial growth factor [43, 44]. A triple drug “cocktail”,
manumycin A, combretastatin A4 phosphate (CA4P), and paclitaxel developed by Yeung and
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co-workers, assured a great promise in the treatment of several ATC cell lines without showing a
significant toxicity in mice [43, 45, 46].
Despite the elusive mechanism behind these anticancer activities, some manumycin
metabolites seem to elicit the cell death through the inhibition of the RAS farnesyltransferase
(FTase). RAS FTase catalyzes the linkage between a farnesyl pyrophosphate and the C-terminal
Cys residue of RAS, an essential modification step to anchor the RAS to the cellular membrane
for its function. As a binary enzyme switching between the active and inactive form, RAS
protein is a key player to regulate the cell growth and malignant transformation. The mutation of
ras oncogene frequently results in its consistent activation, which is associated with 30% to 50%
of lung and colon carcinomas and up to 90% of human pancreatic cancers. Thus, one
chemotherapeutic treatment for these cancers is to suppress the RAS activity by inhibiting the
RAS FTase [47]. For example, manumycin A has been shown to slow down the growth of
human hepatoma cell line via inhibiting the Ras activity [48]. Moreover, manumycin A, B, and C
specifically inhibit the FTase activity but not the closely-related geranylgeranyltransferase
(GGTase), which allows the normal cell to survive by bypassing the FTase deficiency through
GGTase [40, 49]. Due to a high potency against the tumor cells but a low cytotoxicity towards
the normal cells, these compounds hold great promise in the chemotherapeutic application.
Besides the inhibition of RAS FTase, manumycin A can trigger the cell death through
some FTase-independent pathways. One study showed that manumycin A caused the death of
the breast cell lines and thyroid cells by induction of the reactive oxygen species (ROS), such as
nitric oxide (NO•) and superoxide anion (•O2-), triggering the downstream caspase-independent
dsDNA breakages [50]. Another report claimed that manumycin A stimulated apoptosis of
lymphoid tumor and myeloma cell lines due to the caspase-dependent ROS induction [51]. Most
recently, the manumycin family compounds have been confirmed to suppress the oncogenesis by
9

inhibiting the IκB kinase β (IKKβ) activity, possibly through a covalent dimerization of IKKβ
[52]. These findings provided more information on how the cancer cells were killed by the
manumycin compounds.
Inhibition of Interleukin-1β Converting Enzymes
Interleukin-1β converting enzymes cleave the inflammatory cytokines, interleukin-1β and
interleukin 18, to generate the active form of peptides to trigger the inflammatory cascade.
Manumycin metabolites, EI-1511-3, -5, EI-1625-2, manumycin A, B, G, U-56,407, and entalisamycin, reveal not only the inhibitory activity against interleukin-1β converting enzymes, but
also suppress the secretion of interleukin-1β [16, 53]. Notably, the inhibition of the interleukin1β secretion but not for the interleukin-1β converting enzymes is no longer sustained, once the
lower polyketide and a C5N moiety of these manumycin compounds were removed.
Inhibition of Acetylcholinesterase
Recently, manumycin A, B and C were found to serve as a specific acetylcholinesterase
(AChE) inhibitor, which might lead to potential drug development for Alzheimer’s disease
treatment [54]. Found in the neuromuscular junctions and cholinergic synapses of the central
nervous system, AChE catalyzes the degradation of the neurotransmitter, acetylcholine (ACh), to
give choline and acetate to terminate the synaptic transmission. Thus, the AChE inhibitor can
boost the cholinergic synapse activity via the increasing ACh availability. Manumycin A, B and
C could inhibit the AChE comparable to the commercial available Tacrine (Cognex®, 1993) but
with much better specificity, as these three compounds did not exhibit any inhibitory activity on
butyrylcholinesterase (BuChE), which causes Tacrine’s major hepatotoxic side effects during
therapeutic treatment. The epoxide of the mC7N core likely plays an essential role, as
manumycin D, the type II form of manumycin A, failed to inhibit the AChE activity.

10

Biosynthetic Study
The biosynthetic study of manumycin compounds has been focusing on manumycin A
and asukamycin. These two compounds may reflect the biosynthesis of other family member, as
a majority of the manumycin metabolites share an identical lower triene polyketide, primed with
an mC7N core and ended up with a C5N ring. A rational biosynthetic route has been proposed in
according to a series of chemical feedings, while little biochemical or genetic data was available
before this study except for the cloned 5-aminolevulinic acid synthase (ALAS) gene published
by Petricek group [21].
mC7N Core
The mC7N core moiety of manumycin metabolites arises from 3-amino-4hydroxybenzoic acid (3,4-AHBA) instead of 3-amino-5-hydroxybenzoic acid (3,5-AHBA), the
common building block for ansatrienin A, rifamycin B and mitomycin C [55]. Feeding labeled
3,4-AHBA, Zeeck group has first isolated the 64-3,4-AHBA2, a proto-type of manumycin A in
the culture of S. parvulus Tü64 [56, 57]. Gould and co-workers proposed that 3,4-AHBA is the
real precursor of manumycin compounds [58], and Floss group further confirmed this
speculation through a successful feeding of 3,4-AHBA to asukamycin and manumycin A [19]. In
addition to manumycins, 3,4-AHBA is also a biosynthetic precursor for 4-hydroxy-3nitrosobenzamide and grixazone found in Streptomyces murayamaensis and Streptomyces
griseus, respectively (Fig. 1.3) [58, 59].
Polyketide Chains and the Cyclohexane Moiety
Feeding experiments with either [1-13C]-acetate or [2-13C]-acetate indicated that the
lower and upper trienes were built up using three malonyl CoA extenders through the polyketide
condensations (Figure 1.4) [60]. The polyketide-derived biosynthesis was also supported by the
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effusive incorporation of [1-13C,18O]-acetate at C-13 and C-1’ position in asukamycin. Despite
these, it is unclear whether a multi-domain type I or an iterative type II polyketide synthases
(PKS) with discrete functional units is involved in the chain assembly.

Figure 1.3 3,4-AHBA derived natural products. 3,4-AHBA is the common precursor of
manumycins, grixazones, and 4-hydroxy-3-nitrosobenzamide.

Figure 1.4 Biosynthetic origin of asukamycin.
12

Feeding pattern of labeled glycerol demonstrated that the origin of the cyclohexane
moiety, CHC-CoA, is derived from shikimic acid [60]. In fact, this cyclohexane moiety has been
widely found in other natural products, such as ansatrienin [61], doramectin [62],
phoslactomycin [63], all of which were proved to arise from the shikimate pathway via the
chemical feeding and genetic studies (Fig. 1.5). A gene set, ansJKLM/chcA, involved in the
CHC-CoA biosynthesis of ansatrienin has been well characterized in Streptomyces collinus [62].
Additionally, Floss and co-workers has managed to generate a series of novel manumycin
compounds, such as cyclopropyl-, cyclobutyl-, cyclopentyl- and cycloheptyl-asukamycin by
feeding with various ring sizes of carboxylates to S. nodosus (Table 1.1).
Alternatively, the CHC-CoA can also be recruited to form ω-cyclohexyl fatty acids as a
part of cellular membrane components in S. nodosus subsp. asukaensis (Fig. 1.5) [10]. Notably,
the incorporation of CHC-CoA to give cyclohexyl fatty acids also occurs in other
microorganisms, including the Alicyclobacillus acidocaldarius and the ansatrienin producer S.
collinus [62, 64]. As the membrane fluidity and permeability are strongly determined by the fatty
acid composition, the biosynthetic regulation of each fatty acid component is crucial for
membrane homeostasis in bacteria [65, 66]. The content of ω-cyclohexyl fatty acids, a byproduct
generated during the peak period of asukamycin biosynthesis, is maintained to be as low as 3%
[10]. This implies that the organism has a control mechanism to balance the metabolic flux
between the production of membrane fatty acids and asukamycin.
The C5N Moiety
The lower polyketide chain of asukamycin terminates with a 2-amino-3hydroxycyclopent-2-enone (C5N) moiety, an enol tautomer of the 2-aminocyclopentanedion.
This nitrogen-containing five membered cyclic ring also serves as a structural component in
many other natural products, such as reductiomycin, moenomycin A, virustomycin A,
13

Figure 1.5 CHC-CoA derived natural products.
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bafilomycin B1, ECO-02301, ECO-0501, and the majority of manumycin metabolites (Fig. 1.6)
[21, 67-72]. Feeding experiments illustrated that a glycine and a succinyl-CoA are the building
blocks for this C5N moiety (Fig. 1.4) [60, 73]. Moreover, the labeled 5-aminolevulinate (5-ALA)
was found to be incorporated in a low efficiency to the reductiomycin biosynthesis of
Streptomyces xanthochromogenus, implying that 5-ALA could be a close precursor of the cyclic
C5N structure.
5-ALA is an essential precursor for the assembly of tetrapyrrole, which is further
converted to hemes, chlorophylls, billins and corrinoids in many organisms [74]. Two
biosynthetic routes have been described to form this primary metabolite (Fig. 1.7). In plants and
many bacteria, 5-ALA arises from a glutamate-tRNA through the C5 pathway, which requires the
consecutive actions of a glutamyl-tRNAGlu reductase (Gtr) and a glutamate-1-semialdehyde 2,1aminomutase [75]. To animals, fungi, and some other bacteria, the 5-ALA formation is governed
by the Shemin pathway, where the 5-ALA synthase catalyzes the condensation between a
glycine and a succinyl-CoA to give 5-ALA [75]. S. nodosus subsp. asukaensis employs the C5
pathway to form 5-ALA, as the growth of the gtr mutant highly relies on the addition of 5-ALA
to the culture [21].
Encoding a putative 5-ALA synthase to catalyze the condensation between a glycine and
a succinyl-CoA, the cloned hemA-asuA (herein named as asuD2) is essential for the asukamycin
biosynthesis, as the asuD2 mutant failed to produce asukamycin in S. nodosus [21]. Interestingly,
neither the accessible C5 pathway can compensate the asuD2 deficiency to continue the
production of asukamycin; nor the AsuD2 is capable of providing a sufficient 5-ALA to sustain
the survival of the gtr mutant (Fig. 1.7). These seemingly contradictory observations implied that
AsuD2 might have an unknown or additional functional activity compared with other
characterized 5-ALA synthases.
15

Figure 1.6 Examples of natural products containing C5N moiety. The C5N moieties are
indicated in green.

16

Figure 1.7 C5 and Shemin pathways for the 5-ALA formation. The question marks indicate
the dubious steps. The dashed arrow and enzyme indicate the standard 5-ALA synthase that
might not present in S. nodosus.
To date, the mechanism behind the intramolecular cyclization of the C5N moiety remains
to be clarified. Besides, the amino group of C5N moiety is mostly acylated through an amide
bond to a polyenoic acid component of polyketide, with the exception of moenomycin A (Fig.
1.6). The amide-forming enzyme committed in this step is still unknown. Due to the stability
issues, there has yet been a successful feeding experiment using a C5N or its derivatives such as
2-amino-3-hydroxycyclopent-2-enone, or 2-amino-3-hydroxycyclopent-2-enone hydrochloride
(Hu Y., Floss H., unpublished).
The Oxygenation of Protoasukamycin to Form Asukamycin
The two oxygen atoms, positioned in the C4 hydroxyl group and the C5-C6 epoxy group,
had been proved to arise from the atmosphere O2 through the feeding experiment (Fig. 1.4) [76].
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Notably, all the isolated manumycin metabolites from each individual producing organism
feature a unique stereochemistry with either all 4S, 5R, 6S or all 4R, 5S, 6R. For example, both S.
parvulus and S. nodosus generate an identical 4S, 5R, 6S core of manumycins and asukamycins,
while alisamycin and nisamycin, characterized with a 4R, 5S, 6R configuration, are solely found
in Streptomyces K106. These observations strongly suggested that the oxygenation does not
occur spontaneously, and likely requires the involvement of enzymes.
The 13C-labeled feeding study has shown that protoasukamycin C1 is the precursor of
asukamycin A1 in S. nodosus subsp. asukaensis [20]. The structure analysis indicates that the 2amino-4-hydroxy-5,6-epoxycyclohex-2-enone core of asukamycin bears a resemblance with the
epoxyquinone moiety of the Vitamin K-2,3-epoxide and LL-C10037R, in which the epoxide
oxygen atom is recruited from the atmosphere O2 through the action of a dioxygenase
dihydrovitamin K epoxidase and a 2,5-dihydroxyacetanilide epoxidase respectively (Fig. 1.8) [9,
20, 38, 77-80]. Nevertheless, the 18O2 feeding has specified that the hydroxyl and the epoxide
oxygen atoms positioned at the C4 and C5-C6 positions of manumycin A were incorporated
independently from the air oxygen, possibly through a two-step oxygenation mechanism in S.
parvulus Tü64 [76].

Research Objects
1. Identification of the Asukamycin Biosynthetic Genes
(1) To find the conserved gene probes to identify the asu genes.
(2) To clone and sequence the asu genes from a cosmid library.
(3) To functionally express the entire asu cluster in a heterologous strain.
(4) To justify a minimal set of the asu gene cluster.
2. Genetic and Biochemical Studies of the asu Genes
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Figure 1.8 Previously proposed dioxygenase mechanism for asukamycin biosynthesis based
on the formation of Vitamin K oxide and LL-C10037α.
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(1) Genes involved in the biosynthesis of the 3,4-AHBA core.
(2) Genes responsible for the C5N moiety formation.
(3) Genes in control the assembly of the upper and lower triene polyketides.
(4) Genes acting on the formation of two amide bond linkages.
(5) Genes governing the oxygenation of protoasukamycin to give asukamycin.
3. Characterization of the Asukamycin Biosynthetic Pathway.
(1) To explore the novel intermediates and pathway related products.
(2) To determine the timing for the assembly of the building blocks.
(3) To dissect the biosynthetic routes for asukamycin and its congeners.
(4) To investigate the interaction between the formations of asukamycin and the cellular fatty
acids.
(5) To assess and revise the current biosynthetic model.
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CHAPTER TWO:
IDENTIFICATION AND CHARACTERIZATION OF THE ASUKAMYCIN
BIOSYNTHETIC GENE CLUSTER
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Introduction
Owing to the accumulated genetic and biochemical data, the biosynthetic genes for a
natural product can be targeted from the genomic library using a DNA probe, designed and
amplified based on a conserved protein involved in the assembly of a similar structural moiety.
For example, genes coding for TDP-D-glucose 4,6-dehydratase and halogenase were used to fish
the biosynthetic gene clusters of kanamycin and kutzneride, respectively [81, 82]. As secondarymetabolite biosynthetic genes tend to be clustered in prokaryotes, the identification of one gene
could lead to the revealing of the entire gene cluster in its vicinity.
Asukamycin contains several characteristic structural moieties, such as a cyclohexane
group, a C5N ring, an mC7N core, and two triene polyketides. Due to the specificity problem of
the polyketide synthases (PKS), it could be difficult to pinpoint the dedicated genes for the triene
formation, particularly in the presence of many irrelevant PKSs involved in the biosynthesis of
other secondary polyketide metabolites. The genes responsible for the formation of a unique
cyclohexane group can be targeted by the gene set, ansJKLM/chcA, which had been proved to
govern the CHC-CoA assembly in ansatriene biosynthesis [62]. To target the C5N moiety, we
can choose either the asuD2, the only gene reported to condense the glycine and succinyl-CoA
precursors in the asukamycin biosynthesis.

Results
Identification and Cloning of the Asu Cluster
To identify the asukamycin biosynthetic gene cluster, a cosmid genomic library of S.
nodosus subsp. asukaensis was constructed and screened with two
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P-labelled DNA probes.

Encoding the 1-cyclohexenylcarbonyl CoA reductase involved in the assembly of cyclohexane
moiety for the ansatrienin biosynthesis in Streptomyces collinus, the chcA identified two
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cosmids, 2B9 and 10D6, which revealed a 1.8 kb overlapping region of the cloned DNA inserts
[62]. Encoding a 2-oxoamine synthase for the C5N moiety formation of asukamycin, the asuD2
only hybridized with cosmid 10D6 [21]. As cosmid 10D6 was picked out by both probes, we
predicted that the overlapping 10D6 and 2B9 likely covers large part of the asukamycin
biosynthetic gene cluster. Thus, these two cosmids were mapped and sequenced to disclose a
total combined 63,922 bp of DNA inserts (GeneBank accession No. GQ926890). DNA sequence
analysis revealed 36 potential open reading frames, tentatively assigned as the asu genes,
encoding for the gene products potentially involved in the asukamycin biosynthesis and
regulatory activities (Fig. 2.1 and Table 2.1).
Heterologous Expression of the Asu Cluster
DNA analysis has preliminarily allocated the crucial genes required for the compilation
of the building blocks (asuA-E groups), such as the 3,4-AHBA, the cyclohexanyl carboxylate
and the 2-amino-3-hydroxy-cyclopent-2-enone (C5N) components, the upper and lower
polyketide chains assembly, and the post-assembly oxygenation of the protoasukamycin. Also
proposed were the genes tentatively involved in the regulation (asuR) and the exportation of the
newly formed asukamycin metabolites outside the cells (asuM1). To confirm that the cloned
region contained all the genes in control of the biosynthesis, regulation and self-immunity, a
series of heterologous expression experiments were conducted in the asukamycin nonproducing
Strptomyces lividans K4-114. Because neither of the cloned cosmids carried the full gene sets
mentioned above, we intended to reassemble the cosmids 2B9 and 10D6 into one single clone.
To combine two large DNA fragments, the conventional digestion/ligation cloning
strategy has several shortcomings. For example, the choice of a unique cloning restriction site
can be limited, and the large ligation products can also lead to low transformation efficiency. To

23

Figure 2.1. Open reading frames identified in the asu cluster. The putative genes were divided into eight groups based on the
functional characterization. Group A: 3,4-AHBA biosynthesis and adenylation; Group B: CHC-CoA biosynthesis; Group C:
polyketide chain assembly; Group D: C5N moiety biosynthesis; Group E: oxygenation; Group R: transcriptional regulation;
AsuM1: efflux protein. The relative genomic regions and overlapping inserts of three cosmid clones 2B9, 10D6, pART1361, and
pART1391 are indicated with bold lines.
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Table 2.1 Deduced functions of ORFs in the asukamycin biosynthetic gene cluster.
Protein

aa

Homolog (Accession No.)

Identified or Proposed Function

AsuA1

372

GriH (YP_001825760.1)

3,4-AHBA synthase

AsuA2

471

ACMS I (AAD30111.1)

3,4-AHBA carboxyl group adenylation

AsuA3

278

GriI (BAF36651.1)

Condensation of ASA and DHAP

AsuB1

983

PlmJK (AAQ84158.1)

EPSP synthase/CHC-CoA ligase

AsuB2

394

PlmL (AAQ84159.1)

Acyl-CoA dehydrogenase

AsuB3

277

ChcA (AAC44655.1)

1-cyclohexenylcarbonyl CoA reductase

AsuB4

667

PlmM (AAQ84161.1)

2,4-dienoylCoA reductase

AsuC1

219

Sfp (pdb|1QR0)

Phosphopantetheinyl transferase

AsuC2

269

GdmF (AAO06919.1)

Arylamine N-acyltransferase

AsuC3

338

ZhuH (pdb|1MZJ)

Asukamycin ketosynthase III

AsuC4

361

ZhuH (pdb|1MZJ)

Asukamycin ketosynthase III

AsuC5

84

ZhuG (AAG30194.1)

Asukamycin KSIII associated ACP

AsuC6

151

PaaI (P76084)

Thioesterase

AsuC7

234

Sco1815 (pdb|2NM0)

Ketoreductase

AsuC8

152

HadC (NP_215151.1)

Acyl dehydratase

AsuC9

150

HadB (YP_001281933.1)

Acyl dehydratase

AsuC10

94

Putative ORF

Unknown

AsuC11

91

ZhuN (AAG30201.1)

KSI/II associated ACP

AsuC12

87

AcmACP (AAD30112.1)

3,4-AHBA carrier protein

AsuC13

397

FabF(pdb|2GQD)

Asukamycin ketosynthase I/II

AsuC14

240

FabF (pdb|2GQD)

Asukamycin ketosynthase I/II

AsuC15

260

RifR (pdb|3FLB)

Type II thioesterase

AsuR1

242

GerE (pdb|1FSE)

Transcriptional regulation

AsuR2

191

TetR family protein

Transcriptional regulation

AsuR3

307

Membrane protein

Transcriptional regulation

AsuR4

141

DNA-binding protein

Transcriptional regulation

AsuR5

254

FarR3 (BAG74713.1)

Transcriptional regulation

AsuH1

384

Putative ORF

Unknown

AsuR6

280

GerE (pdb|1FSE)

Transcriptional regulation

AsuE1

407

PHBH (pdb|1YKJ)

Protoasukamycin 4-hydroxylase

AsuE2

185

PheA2 (pdb|1RZ0)

Flavin Reductase

AsuE3

371

LimB (Q9EUT9.1)

4-hydroxyprotoasukamycin epoxidase

AsuD1

531

NovL (AAF67505.1)

Amide synthase

AsuD2

409

MoeC4 (ABJ90148.1)

2-oxoamine synthase

AsuD3

468

MoeA4 (ABJ90146.1)

5-aminolevulinate CoA ligase

AsuM1

512

EmrB (YP_001507963.1)

Asukamycin exporter
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bypass these difficulties, the λ-Red recombination system has been developed [83-87]. This in
vivo recombinant system includes three key proteins, Bet, Exo, and Gam, in which Gam
stabilizes the transformed linear DNA by inhibiting the RecBCD exonuclease, and Bet/Exo
promote homologous recombination [88]. Taking advantage of the innate merit of the two shared
DNA segments of 2B9 and 10D6, the pOJ446 vector and the overlapping 1.8 kb inserts region,
we further simplified the established λ-RED recombination system by skipping the conventional
PCR cloning and multiple “stitching” processes, and assembled two cosmids in a single step [8486, 89] (Fig. 2.2). 2B9 and 10D6 were linearized by the unique cut restriction enzymes SpeI and
XbaI, respectively. The linearized cosmids are unable to replicate, while the circular recombinant
clones resulted from two cosmids will propagate and form colonies under the apramycin
antibiotic selection. The resulting cosmid, pART1361, was introduced into the S. lividans K4114 by conjugation from the E. coli strain.
Carrying the pART1361, the S. lividans transformant produced the brightly yellowish
metabolites, which displayed an inhibitory effect against Staphylococcus aureus. HPLC analysis
detected a group of compounds with an identical UV absorption spectrum and the similar solvent
mobility as the asukamycin metabolites A1-A7 observed in S. nodosus subsp. asukaensis (Fig.
2.3). The production of asukamycin and congeners A1-A7 were further confirmed by a highresolution LC-MS. In the meantime, the ω-cyclohexyl fatty acids were also detected at 7.8% in
the S. lividans K4-114 by GC-MS. Notably, the productivity of asukamycin was more stable and
persistent in S. lividans K4-114 in comparison with its natural host S. nodosus subsp. nodosus,
possibly due to the imposed apramycin antibiotic selection.
In pART1361, located on one end of the insertion were many ORFs related to the
primary metabolic functions of Streptomcyes species but unlikely involved in the asukamycin
biosynthesis. To further justify the boundaries of asu cluster, we eliminated this 25.4 kb region
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Figure 2.2 Assembly of two cosmids with overlapping inserts. a, cosmids 2B9 and 10D6 were
linearized by SpeI and XbaI, respectively. Homologous recombination occurred at two
overlapping insert and vector regions, indicated by heavy lines. b, the restriction map of 2B9,
10D6 and pART1361. The inserts are shown with solid lines. The EcoRI fragment sizes are
indicated (kb). c, comparison of the EcoRI digestion patterns by DNA gel electrophoresis.
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Figure 2.3 HPLC analysis of the S. nodosus WT and the S. lividans K4-114 transformants.
Twenty μL of crude culture extract of the S. lividans K4-114/pART1391 (a), the S. lividans K4114/pART1361 (b), the control S. lividans K4-114/pOJ446 (c), and the S. nodosus subsp.
asukaensis wild type strain (e). The arrows identify the peaks of asukamycin A1 and related
metabolites, A2-A5, B1-B4. The x axis indicates the time (min); y axis indicates the absorbance
abundance (mAu).
by replacing it with the spectinomycin resistance gene to give a pART1391. The HPLC, highresolution MS, and bioassay further supported that S. lividans K4-114/pART1391 was fully
capable of producing asukamycin A1 and its congeners A2-A7. These expression results indicate
that the cloned 36 asu genes in pART1391 are sufficient for the asukamycin production.

Disscussion
The chemical structure of asukamycin features two triene polyketide chains locked on a
3,4-AHBA-originated mC7N core. The lower chain ends with a C5N structural moiety, while the
upper one starts with a cyclohexane head group. From the sequence analysis, four major groups
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Figure 2.4 Construction of pART1391. a, spectinomycin resistance gene cassette (spec) was
PCR amplified from pIJ778 using primers AsuRED-4 and -6. b, the λ-RED based recombination
was conducted to replace the 25.4 kb insert region of pART1361 with a spec cassette to create
pART1391. The predicted EcoRI digestion fragments are indicated (kb).c, comparison of the
EcoRI digestion pattern by DNA gel electrophoresis. Note: Lane pART1381 indicates another
pART1361 derived cosmid clone which is not related to this study.
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of the asu genes were proposed to be involved in the structural assembly, including the asuA for
the biosynthesis and activation of 3,4-AHBA, the precursor of the mC7N core, the asuB for the
conversion of shikimate to form CHC-CoA, the asuD for the C5N formation, and the asuC group
for the lower and upper polyketide chain assembly (Fig. 2.1). Besides, the sequenced genomic
region also covers the putative regulatory genes and an exporter coding gene. The identification
and the subsequent functional expression of the asu cluster provided a platform for the further
investigation of these biosynthetic genes.
Heterologous expression of the entire gene cluster is not only a strategy to confirm the
putative biosynthetic genes, but also an ideal approach to delineate the boundaries, justify the
sufficiency, and set a stage for engineering of the targeted gene cluster. However, the frequently
encountered difficulty is that the intact cluster is not accommodated by one clone from the
genomic library. For example, cosmid 2B9 and 10D6, together but not one of the two,
encompasses all the asu genes. To add or trim large genomic DNA regions on a cosmid clone,
the λ-Red recombination system has been well developed due to the simplicity and high fidelity
compared with the conventional molecular cloning [83-87]. Recently, Bachmann group
developed a method to combine two overlapping cosmids, which required three times of λ
recombinations and a single unique restriction site in the overlap region [85]. Besides, a
redundant DNA “scar” sequence was also added in the resulting cosmid.
In this study, taking advantage of the innate merit of the two shared DNA segments, the
vector and the overlapping inserts region, we further simplified this system by skipping the
conventional PCR cloning and multiple “stitching” processes, and assembled two cosmids in a
single step (Fig. 2.2). The target cosmids can be linearized by the restriction enzyme digestion,
as a majority of commercial cosmid vectors carry multiple rare cut restriction sites such as XbaI
and SpeI on the pOJ446. The linearized cosmids are unable to replicate, while the circular
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recombinant clones resulted from two cosmids will propagate and form colonies under the
antibiotic selection. This straight-forward recombination approach is particularly useful to
examine the competence of the cloned genes, and provide a convenient platform for the further
gene manipulations. In this study, the productivity of asukamycin was found more consistant in
the S. lividans K4-114 introduced with the recombinant pART1361 than its natural producer S.
nodosus subsp. asukaensis, possibly due to the antibiotic selection pressure. As to be mentioned
in later chapters, a reliable yield of the novel intermediate 4-hydroxylprotoasukamycin D1 was
also detected in the S. lividans K4-114 carrying the pART1361E3, which was further generated
from pART1361 based on the straight-forward λ-Red PCR strategy by replacing the asuE3 with
a spectinomycin resistance gene.
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CHAPTER THREE:
FORMATION OF THE ASUKAMYCIN LOWER CHAIN
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Results
3,4-AHBA Formation
Feeding experiments demonstrated that the mC7N core structure is resulted from the
precursor 3,4-AHBA in the asukamycin biosynthesis [19, 58]. Two genes in the cloned asu
cluster, asuA1 and asuA3, are closely related to the griH and griI involved in the grixazone
biosynthesis in Streptomyces griseus [59]. GriI catalyzes an aldol condensation using Laspartate-4-semialdehyde (ASA) and dihydroxyacetone phosphate (DHAP) to form a putative
intermediate 2-amino-4,5-dihydroxy-6-one-heptanoate-7-phosphate, which could be further
converted to 3,4-AHBA by GriH, an intra-molecular cyclase. Notably, the griH and griI locate
side-by-side in the genome of S. griseus, while the asuA1 and asuA3 separate apart from each
other by eight additional ORFs. To confirm their roles in 3,4-AHBA formation of asukamycin,
we constructed two mutants by disrupting the corresponding asuA1 and asuA3. Neither 3,4AHBA nor asukamycin were detected in these mutants (Fig. 3.1). The asukamycin production
can be further restored with the addition of 3,4-AHBA in both mutant cultures. Moreover, LCMS analysis revealed a small amount of the novel products, E1 and E3/E4, which possess a C5N
moiety amide-linked with the triene upper chains corresponding to A1 and A3/A4, respectively
(Fig. 3.2).
Activation of 3,4-AHBA
Previous feeding studies indicated that the lower polyketide chain assembly begins on
3,4-AHBA as a starter building block [60]. According to several polyketide/polypeptide
biosynthetic systems that employ AMP-linked aroyl starters [90-92], 3,4-AHBA is presumably
activated via adenylation and then tethered to a specific aroyl carrier protein (ArCP) for the
downstream chain extensions. Located immediately downstream of the asuA1, the asuA2 is
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Figure 3.1 HPLC analysis of the asuA1 and asuA3 mutants. Twenty μL of crude culture
extract of the asuA1 mutant (a), the asuA3 mutant (b), the asuA1 mutant supplemented with 3,4AHBA (c), the asuA3 mutant supplemented with 3,4-AHBA (d), and the S. nodosus subsp.
asukaensis wild type strain (e). The arrows identify the peaks of asukamycin A1 and related
metabolites, A2-A5, B1-B4. The x axis indicates the time (min); y axis indicates the absorbance
abundance (mAu).
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Figure 3.2 Proposed structures of E1 and E3/E4. The exact mass of E1 is 301.1670
(calculated for C18H23NO3, 301.1678; mass error, 3.30 ppm) with a fragment 189.1272
(calculated for C13H17O, 189.1279). The exact mass of E3/E4 is 275.1501 (calculated for
C16H21NO3, 275.1521; mass error, 7.58 ppm) with a fragment 163.1105 (calculated for C11H15O,
163.1123).
homologous to the coding gene for the actinomycin synthetase I (ACMS I), which initiates the
actinomycin

formation

in

Streptomyces

chrysomallus

by

activating

4-methyl-3-

hydroxyanthranilate (4-MHA) in the presence of ATP [90]. To examine the function of AsuA2,
we constructed a mutant by replacing asuA2 with an apramycin resistant cassette. The asuA2
mutant failed to produce asukamycins, but accumulated 3,4-AHBA through HPLC analysis (Fig.
3.3). The detected 3,4-AHBA also could complement the asukamycin production of the 3,4AHBA-deficient asuA1 mutant upon co-culturing (Fig. 3.4). Located seven ORFs upstream of
the asuA2, the asuC11 and asuC12 both belong to the gene family coding for the acyl carrier
protein (ACP). AsuC12 is distinctly related to AcmACP, a specific ArCP of the actinomycin
pathway, which escorts the priming molecule 4-MHA-AMP to the peptide synthase AcmII for
chain initiation [90]. The mutant in which both asuC11 and asuC12 were truncated showed a
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similar phenotype as the asuA2 mutant, i.e., 3,4-AHBA accumulation and no asukamycin
production (Fig. 3.3 and 3.4).

Figure 3.3 HPLC detection of 3,4-AHBA in the asuA2, asuC11C12, and asuC13 mutants.
200 μL of crude culture extract from the aqueous layer of the asuA2 mutant (a), the asuC13
mutant (b), the asuC11C12 mutant supplemented (c), and the control group, asuA1 mutant (d).
The dash line identifies the peaks of 3,4-AHBA. The x axis indicates the time (min); y axis
indicates the absorbance abundance (mAu).
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Figure 3.4 HPLC analysis of the asuA2, asuC11C12, and asuC13 mutants. Twenty μL of
crude culture extract of the asuA2 mutant (a), the asuC13 mutant (b), the asuC11C12 mutant (c),
the S. nodosus subsp. asukaensis wild type strain (g), and 100 μL crude co-culture extract of the
asuA2 and the asuA1 mutant (d), the asuC13 and the asuA1 mutant (e), the asuC11C12 and the
asuA1 mutant (f).
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Assembly of Lower Polyketide Chain
Positioned next to the asuC12, the asuC13 has strong similarity to a group of genes
encoding for the type II iterative fatty acid/polyketide synthases (FAS/PKS) [93, 94]. Besides
featuring a putative Cys151-His285-His322 catalytic triad, AsuC13 also holds several conservative
hydrophobic residues, which have been depicted to form a pocket to accommodate the ongoing
acyl intermediate in the bacterial fatty acid synthases [95-97]. As the constructed asuC13 mutant
failed to produce asukamycins and accumulated 3,4-AHBA, similar to the asuA2 and
asuC11C12 mutants, AsuC13 was confirmed to be a KSI/II polyketide synthase involved in the
lower polyketide chain assembly (Fig. 3.3 and 3.4). Notably, trace amounts of E1 and E3/E4
were also found in this mutant culture as observed in the asuA1 and asuA3 mutants. Immediately
downstream of asuC13, the asuC14 encodes a protein homologous to AsuC13, except for a
truncated N-terminus and lacking the characteristic Cys-His-His catalytic triad. Coincidently,
this uncommon asuC13/asuC14 gene pair, in which an intact polyketide synthase gene
accompanies a partially truncated partner, is also present in the uncharacterized gene clusters
from the genomic sequencing projects of Streptomyces hygroscopicus (ZP_05513707-8) and
Salinispora arenicola (YP_001535964-5 and YP_001537504-5). So far, the AsuC14 function
remains unknown.
Two additional reactions, a β-keto reduction and a dehydration, are required in the
formation of the lower triene polyketide. Sequence analysis revealed that only one set of genes,
the asuC7-C9, could fulfill these anticipated functions in the cloned asu cluster. AsuC7 displays
a high homology to several polyketide ketoreductases (KR), including the bacterial FabG
proteins, the SCO1815 from Streptomyces coelicolor, and the MabA from Mycobacterium
tuberculosis [98, 99]. Two putative dehydratase genes asuC8 and asuC9 were found downstream
of asuC7. AsuC9 contains a typical hydratase motif with the catalytic residues Asp37-X(4)-His42
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and is closely related to the HadB, which forms a heterodimer with either the HadA or HadC to
act on the compilation of the long chain mycolic acids in M. tuberculosis H37Rv [100-103].
Coincidently, AsuC8 is highly related to both HadA and HadC. As asuC7 and asuC8,C9 are the
only genes in the cluster which could be involved in β-keto reduction and dehydration of the
polyketide, we suggest that they operate in the assembly of the lower as well as the upper trans
triene chains (to be discussed in the following chapter).

Discussion
3,4-AHBA is a common precursor for several natural products, such as manumycin A-C,
grixazones, and 4-hydroxy-3-nitrosobenzamide in the corresponding Streptomyces parvulus,
Streptomyces griseus, and Streptomyces murayamaensis. These cloned biosynthetic genes, asuA3
and asuA1, could serve as probes to fish other gene clusters for these 3,4-AHBA related
metabolites. By using their homologous gene probes, griI and griH, Ohnishi and co-workers
recently identified the 4-hydroxy-3-nitrosobenzamide biosynthetic gene cluster [104]. Moreover,
the genome mining could further extend to a long list of asuA3 and asuA1 homologs deposited in
GenBank to explore the 3,4-AHBA related natural products.
The results indicate that 3,4-AHBA is activated by AsuA2 to form an acyl-AMP,
subsequently loaded onto the aroyl carrier protein AsuC12 to initiate the lower polyketide
assembly (Fig. 3.5). Construction of the lower polyketide chain likely requires a set of type II
polyketide synthetic enzymes including the KSI/II AsuC13,C14, the KR AsuC7 and the DH
AsuC8,C9, based on the sequencing and mutagenic analysis (Fig. 3.5). AsuC13 and AsuC14 are
most likely responsible for the initiation and two further rounds of polyketide chain extensions,
as the lower chain biosynthesis was abolished in the asuC13 mutant. The presence of asuC14
might not be coincidental. AsuC13 and AsuC14 could function together to constrain the growing
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triene structures and control the polyketide chain length. Further studies on other manumycin
biosynthetic genes should provide more clues on the function of asuC14. Since the asuC11 is
potentially organized in the same transcription unit with the asuC12-C14, AsuC11 ACP could be
involved in the second and the third rounds of lower chain polyketide extensions.
Interestingly, governing the lower chain biosynthesis, asuA1-A3 and asuC11-C14 are
discretely located, while their homologs in S. hygroscopicus, ZP_05513702-8, are organized in a
seven-gene cluster, and likely function in a sequential order, suggesting that asukamycin
biosynthesis has evolved through multiple horizontal gene transfer events and possibly an
extensive genomic rearrangement in S. nodosus subsp. asukaensis.

Figure 3.5 Proposed biosynthetic pathway of asukamycin lower chain.
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CHAPTER FOUR:
ASSEMBLY OF THE ASUKAMYCIN UPPER CHAIN
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RESULTS
Cyclohexylcarbonyl-CoA Formation
Unlike other manumycins, the formation of the asukamycin upper polyketide chain starts
with cyclohexylcarbonyl-CoA (CHC-CoA), which is derived from the primary metabolite,
shikimic acid [60]. Four clustered genes, asuB1-B4, are homologous to two independent gene
sets, ansJKLM/chcA from the ansatrienin producer S. collinus and plmJKLM/chcA from the
phoslactomycin producer Streptomyces sp. HK-803, which are involved in CHC-CoA
biosynthesis [62, 105]. All these CHC-CoA biosynthetic genes are organized in the same order in
these three strains. Notably, AsuB1 and PlmJK are likely bifunctional proteins which contain an
N-terminal 5-enolpyruvylshikimate-3-phosphate synthase (EPSP synthase) domain as well as a
cyclohexanecarboxylate-CoA ligase domain at C-terminus. However, these functional activities
are carried out by two separated protein products AnsJ and AnsK in S. collinus. Constructed by
gene disruption, the asuB1 mutant failed to produce asukamycin, but levels of the previously
identified asukamycin congeners A2-A7 were increased three-fold compared with those of the
wild type strain (Fig. 4.1). LC-MS analysis further identified three new compounds A8, B8 and
C8 (Fig. 4.2 and 4.3). The NMR analysis of B8 revealed a B1-like structure except that the upper
polyketide chain was replaced by an acetyl group (Table 4.1). Based on the molecular weight,
compounds C8 and A8 are likely the proto- and type I-form of B8, respectively. These products
probably resulted from an increasingly buildup of the 3,4-AHBA-lower chain-ACP intermediate.
Besides, GC-MS analysis revealed that the cellular level of ω-cyclohexyl fatty acids were at
7.8% in the S. lividans K4-114/pART1391 but not in the control strain carrying an empty vetor,
suggesting the included asuB1-B4 are sufficient for the CHC-CoA assembly.

42

Figure 4.1 HPLC analysis of the asuB1, asuC3C4 mutants, and the S. nodosus wild type
strain. Twenty μL of crude culture extract of the asuB1 mutant (a), the asuC3C4 mutant (b), and
the S. nodosus subsp. asukaensis wild type strain (c). The arrows identify the peaks of
asukamycin A1 and related metabolites, A2-A5, B1-B4. The y axis indicates the absorbance
abundance (mAu). Panel b was calculated based on a 10X injection amount.
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Figure 4.2 HPLC detection of A8, B8, and C8 in the asuB1 and asuC2 mutants. Twenty μL
of crude culture extract of the asuB1 mutant (a) and the asuC2 mutant (b). An old culture of
asuC2 mutant was shown in panel c. The dash lines identify the peaks of A8, B8, and C8. The y
axis indicates the absorbance abundance (mAu).

Figure 4.3 Molecular structures of A8, B8, and C8.
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Table 4.1 Summary of observed 1H-NMR and 13C-NMR of B8.
Position

δC (ppm)

δH (ppm)

1
2
3
4
5
6ax
6eq
7
8
9
10
11
12
13
1’
2’
1’’
2’’
3’’
4’’
5’’
NH-14
NH-0’

192.6
130.8
129.6
73.0
71.3
40.1

--7.27 (d, J=7.8)
-3.85 (m)
2.71 (dd, J=16.8, 3.2)
2.59 (dd, J=16.5, 6.07)
6.12 (d, J=15.2)
6.43 (dd, J=14.9, 11.5)
6.67 (dd, J=15.1, 10.9)
6.47 (dd, J=15.2, 11.0)
7.12 (dd, J=15.0, 11.5)
6.38 (d, J=15.0)
--1.90 (s)
----

138.4
131.5
138.8
129.5
140.3
124.5
165.0
169.5
23.9

8.91 (s)
8.88 (s)

Note: 13C-NMR and 1H-NMR signals for C1’’- C5’’ are undetectable in DMSO-d6 due to the
coalescence phenomena.
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Assembly of the Upper Polyketide Chain
To initiate fatty acid or polyketide biosynthesis, acyl-CoA starters are recruited and
condensed with a (methyl)-malonyl-ACP by the action of fatty acid synthases FabH or the
polyketide synthases III (KSIII). This is distinct from the action of KSI/II, joining two ACPbound acyl substrates in the subsequent chain extensions in many microorganisms [93, 94]. The
adjacent asuC3 and asuC4 are homologous to numerous genes encoding bacterial FabHs and
KSIIIs including the zhuH of Streptomyces. sp. R1128 [106, 107]. Both AsuC3 and AsuC4
feature a putative CoA binding site and a conserved Cys-His-Asn catalytic triad, which is crucial
for the nucleophilic acyl substitution. As AsuC3 and AsuC4 are highly similar to each other, we
assume that they might act together as a heterodimer to condense the CHC-CoA and malonylACP to give a 3-cyclohexyl-3-oxopropanoyl-ACP intermediate for the downstream polyketide
chain assembly. Interestingly, a double mutation of asuC3 and asuC4 did not completely
eliminate the asukamycin production. The asuC3C4 mutant retained 0.9% asukamycin A1 and
30.0% congeners A2-A7 relative to the wild type strain yield (Fig. 4.1), possibly due to a
functional complementation by the cellular FabH involved in the fatty acid biosynthesis. AsuC5,
presumably organized in the same transcription unit with asuC3,C4, is a zhuG homolog [108].
As ZhuG acts together with ZhuH to initiate the assembly of the antitumor polyketide R1128
[108], AsuC5 may play a crucial role in the beginning round of asukamycin upper chain
assembly. So far, the KSI/II gene(s) required for the second and third round extensions of the
upper chain remain to be identified.
Attachment of the Upper Polyketide Chain
Asukamycin contains two amide bonds, the linkage between the upper chain and the
mC7N core, and the bridge tethering the C5N moiety to the lower polyketide chain. Coincidently,
two putative amide synthase genes, the asuD1 and asuC2, were detected in the cloned cluster.
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Sited together with the asuD2 and asuD3 and possibly sharing the same transcription unit, the
asuD1 is likely involved in the C5N moiety biosynthesis (see the following chapter), while the
asuC2 was detected immediately upstream of the asuC3-C5, presumably organized in the same
transcription unit. AsuC2 is homologous to the family of N-acyltransferases, which contains the
arylamine N-acetyltransferase (NAT 1), Asm9, and RifF from the corresponding Mesorhizobium
loti MAFF303099, Actinosynnema pretiosum subsp. auranticum, and Amycolatopsis
mediterranei S699 [109-112]. An asuC2 disrupted mutant was constructed to confirm its
involvement in the attachment of the upper chain to the 3-amino group of the 3,4-AHBA primed
polyketide intermediate. The production of asukamycins A1-A7 was completely blocked in the
asuC2 mutant. Instead, the N-acetylated compounds A8, B8 and C8 were accumulated, as
observed in the asuB1 mutant (Fig. 4.2 and 4.3). In view of the functional deficiency of asuC2,
these shunt products presumably resulted from the action of a cellular arylamine Nacetyltransferase, commonly found to detoxify arylamine or arylhydroxylamine metabolites
[113, 114].

Discussion
The asuB gene set likely governs the conversion of shikimic acid to give CHC-CoA, the
polyketide starter of asukamycin upper chain, as their homologous genes in S. collinus,
ansJKLM/chcA, were confirmed to be essential for the same conversion by mutation
experiments. Despite that, only the AsuB3 homolog, ChcA, has been proved to catalyze three
independent reactions in vitro, including reductions of 1-cyclohexenylcarbonyl CoA, 5-hydroxy1-cyclohexenylcarbonyl CoA, and 4,5-dihydroxy-1,5-cyclohexadienylcarbonyl CoA (Fig. 4.4)
[115]. In these steps, ChcA reduces α, β-double bonds of either an enoyl or dienoyl CoA
substrate with the same stereochemistry pattern: anti fashion with addition of solvent hydrogen
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to the si face of the α-carbon. Besides, the mutation and in vitro studies demonstrated that the
non-clustered ChcB, a ubiquitous Δ1, Δ2 enoyl CoA isomerase in Streptomyces, is required for
the perultimate step in the CHC-CoA formation.
Sequence analysis indicated that AsuB1 is a bifunctional protein, where the C-terminal
domain is similar to a number of acyl-CoA ligases, implying the role of incorporating a CoA to
the carboxyl group of shikimate [116]. The N-terminal (1-424aa) domain of AsuB1 shows a
relatively weak similarity with the well-characterized EPSP synthase involved in the conversion
of shikimate to form chorismate. Rather than a real EPSP synthase functioning to conjugate PEP
to the shikimate 3-phosphate, AsuB1 may play a role in the 1,4-anti elimination of shikimate or
shikimate 3-phosphate (Fig. 4.4) [62, 116]. Although AsuB2 and AsuB4 are homologous to an
acyl-CoA dehydrogenases and an oxidoreductase, respectively, the exact function of these two
enzymes remain to be determined.

Figure 4.4 Proposed biosynthesis pathway of CHC-CoA in S. nodosus subsp. asukaensis.
Related homologous enzymes are indicated in brackets. The question marks indicate the
unverified roles of the essential enzymes.
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For the assembly of asukamycin upper polyketide, AsuC3,C4 likely initiate the
condensation between CHC-CoA and malonyl-ACP, resembling the bacterial FabH and other
KSIIIs, which are directly primed with an acyl-CoA (Fig. 4.5). In the asuC3,C4 mutant most
asukamycin A1 production was abolished, and levels of the congeners A2-A7 were also reduced
compared to the wild-type. This reflects a possible involvement of the cellular fatty acid synthase
FabH, which displays a substrate preference distinct from AsuC3,C4, priming preferentially with
branched chain acyl-CoAs rather than CHC-CoA, to give a higher yield of A2-A7 relative to A1
[10].

Figure 4.5 Comparison of biosynthetic pathways of asukamycin upper chain, R1128A, and
fatty acids. The ACPs are in capsules. Enzymes dedicated in the first condensation are shown in
blue; the ones responsible for the iterative extensions are indicated in red.
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The involvement of AsuC3,C4 in the second and third chain elongations is less likely, as
FabH catalyzes only the first condensation step and passes the resulting 3-ketoacyl-ACP directly
to another enzyme complex for further reductions and chain elongations. Given that E1 and
E3/E4 were found in the asuC13 mutant, the only recognized KSI/II gene pair, asuC13,C14,
may not play a crucial role in the upper chain assembly, although both the upper and lower
polyketide chains of asukamycin share an identical triene structure. It seems that an unidentified
polyketide KSI/II is required to act together with the KR AsuC7 and DH AsuC8,C9 to carry out
the upper triene polyketide extension. We also cannot rule out the involvement of a cellular
FabB/F-like fatty acid synthase, as the successful heterologous expression in S. lividans implies
that a common KSI/II or FASI/II can fulfill the functional role of this unidentified β-keto
condensation enzyme.
The formation of A1-A4 only differs at the priming step of the upper polyketide chain.
Instead of CHC-CoA starter, A2-A4 employ the branched acyl-CoA thioesters, the
corresponding 2-methylpropionyl-CoA, 2- and 3-methylbutanoyl-CoA, which are predominantly
used for fatty acid synthesis in Streptomyces (Fig. 4.6) [10]. These starters, 2-methylpropionylCoA, 2- and 3-methylbutanoyl-CoA, are derived from the corresponding branched-chain amino
acids, valine, leucine, and isoleucine. In the asuB1 mutant, the absence of CHC-CoA abolished
the entire A1 production and redirected the biosynthetic flux to A2-A4. Since A2-A4 formation
was ten-fold higher in this mutant than in the asuC3,C4 mutant, the majority of A2-A4 upper
polyketide initiation is likely performed by the KSIII AsuC3,C4, and only a minor fraction of
A2-A4 production in the asuB1 mutant as well as the wild type strain is contributed by the FabH
activity. The relatively small amount of A5-A7 production could result from an action of the
primary FAS complex to give 4-methylpentanoyl-, 5- and 4-methylhexanoyl-ACP intermediates.
These ACP-tethered thioesters could be directly recruited by an unidentified KSI/II or FASI/II to
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perform three additional elongations and introduce the characteristic triene in analogy with the
A1-A4 upper chain biosynthesis. These observations are in agreement with the involvement of
FabH and suggest a physiological cross-talk between polyketide and fatty acid biosynthesis.

Figure 4.6 Proposed upper chain assemblies of the asukamycin congeners (A2-A7).
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CHAPTER FIVE:

ASUKAMYCIN C5N MOIETY FORMATION
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Results
Three gene sets have been studied for the C5N moiety formation, including the ones for
moenomycin A, ECO-02301, and ECO-0501 from the corresponding Streptomyces ghanaensis,
Streptomyces aizunensis NRRL B-11277, and Amycolatopsis orientalis [69, 70, 117]. Each
carries three highly conserved genes encoding for a 5-aminolevulinate (5-ALA) synthase-like
enzyme, an acyl-CoA ligase, and an amide synthase. To the asu cluster, three adjacent genes,
asuD1, asuD2, and asuD3, were found and appeared to share a common transcription unit (Fig.
2.1).
Previously identified as HemA-AsuA, AsuD2 belongs to the family of pyridoxal
phosphate (PLP)-dependent 2-oxoamine synthases, including 5-ALA synthase, FUM8, L-serine
palmitoyltransferase (SPT) and 8-amino-7-oxononanoate synthase (AONS), which catalyze the
decarboxylative condensation between an amino acid and an acyl-CoA in the assembly of
corresponding 5-ALA, fumonisin, ceramide-sphingolipid, and biotin [21, 118-121]. The gene
disrupted asuD2 mutant failed to produce the asukamycin products, nevertheless the asukamycin
productivity was recovered by reintroducing an expression plasmid pALS4 carrying the asuD2
[21]. Unexpectedly, the asukamycin production could not be complemented by the existing C 5
pathway, or recovered by adding exogenous 5-ALA to the asuD2 mutant culture, which implied
that AsuD2 functions differently from the well-known 5-ALA synthase in the Shemin pathway
to produce 5-ALA in many organisms (Fig. 1.7).
Despite high overall sequence similarity, AsuD2 possesses a Ser83 instead of a strictly
invariant Thr83 of the 5-ALA synthase subgroup (Fig. 5.1). To examine the essentiality of this
residue for the enzymatic activity, Petricek group constructed a pALS4-S83T with a S83T
replacement in asuD2, which failed to restore the asukamycin production in the asuD2 mutant
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(Fig. 5.2). Surprisingly, the pALS4-S83T complemented a 5-ALA-deficient gtr mutant of S.
coelicolor, which could only grow with 5-ALA supplementation.

Figure 5.1 Sequence alignment of AsuD2 with other 2-oxoamine synthases. The Ser83 or
Thr83 positions are highlighted in red. Sequences of enzymes involved in the C5N moiety
assembly are boxed. The ruler above indicates positions of amino acid residues relative to
AsuD2. The enzymes functions/accession number/original strains: AsuD2
(asukamycin/AAO62615/S. nodosus); Eco-Orf34 (Eco-02301/AAX98209/S. aizunensis); EcoOrf16 (Eco-0501/ABM47017/Amycolatopsis orientalis); MoeC4 (Moenomycin A/ABJ90148/S.
ghanaensis ATCC 14672); MoeA5 (Moenomycin A/ ABJ90153/S. ghanaensis ATCC 14672);
AONS (8-amino-7-oxononanoate/pdb1BS0/E. coli); 5-ALAS-H (5-ALA/NP_000679/Homo
sapiens); 5-ALAS-Y (5-ALA/ NP_010518/Saccharomyces cerevisiae); 5-ALAS-A (5ALA/NP_355550/Agrobacterium tumefaciens); 5-ALAS-R (5-ALA/CAA37857/Rhodobacter
capsulatus)
AsuD3, an acyl-CoA ligase, is proposed to act on the C5N ring formation, since
disruption of the homologous moeA4 in Streptomyces ghanaensis led to accumulation of a
moenomycin A analog lacking the C5N moiety [117]. Located immediately upstream of asuD2,
the asuD1 is closely related to a group of amide synthase genes, including the simL and novL for
the biosynthesis of simocyclinones and novobiocin in Streptomyces antibioticus Tü6040 and
Streptomyces spheroides NCIB 11891, respectively [122-124].
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Figure 5.2 TLC analysis and bioassay of the AsuD1-D3 enzymes. a, and c, chromatograms
visualized under UV 254 nm. b, the same TLC plate was further overlaid with Bacillus subtilis
mixed with nutrient agar and incubated overnight at 37°C. The red arrow shows the newly
formed product 2880-II. Lane 1, the wild type strain; Lane 2, the asuD2 mutant; Lane 3, the
asuD2 mutant/pALS4; Lane 4, the asuD2 mutant/pALS4-S83T; Lane 5, standard asukamycin
(10 μg); Lane 6, S. lividans/pAS9A1; Lane 7,8, S. lividans/pAS9A1 supplemented with ferulic
acid (2.5 mg/ml); Lane 9, standard ferulic acid (10 μg). d, the conversion of ferulic acid to give
2880-II. *Communicated with Petricek group.
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All the asuD1, D2 and D3 mutants failed to produce asukamycin, but accumulated a new
set of metabolites, A1a-A5a, which were shown closely related to the corresponding A1-A5 but
with 95 Dalton less molecular weights, suggesting that the amide-linked C5N moiety of A1-A5
was replaced by a free carboxyl group in A1a-A5a (Fig. 5.3). The corresponding type II
compounds, B1a-B5a, were also present in all three mutants. To confirm the asuD1-D3
involvement in the C5N moiety formation, the asuD1-D3 operon was further cloned under the
control of the constitutive ermE* promoter and expressed in S. lividans. A novel brown
metabolite was detected, but further attempts to characterize the compound have failed so far.
Feeding ferulic acid to this strain, a new compound was obtained with a molecular weight of
290.097 (Fig. 5.2). MALDI-TOF MS-MS analysis of the TLC purified compound revealed an
identical fragmentation pattern as the reported compound 2-(feruloylamino)-3-hydroxypent-2enolone (2880-II) which possesses a C5N moiety connected to the carboxyl group of ferulic acid
[125]. 2880-II could not be formed if any one of the asuD1, asuD2 or asuD3 was omitted from
the expression cassette.

Discussion
The asuD1, D2, and D3 mutants revealed an identical set of accumulated products A1aA5a, indicting their necessity for the assembly and attachment of the last piece of asukamycin
building blocks, the C5N moiety. The sufficiency of AsuD1-D3 for this process was also
supported by the functional expression to convert ferulic acid into 2880-II in S. lividans. As a
member of the 2-oxoamine synthases, the AsuD2 displays a high homology to the 5-ALA
synthase, which is a dedicated enzyme in charge of the condensation of glycine and succinylCoA to form the 5-ALA, a primary metabolite and the possible precursor for the C5N moiety [21,
67, 73]. However, as the AsuD2 and the HemA, a mammalian 5-ALA synthase, were unable to
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Figure 5.3 HPLC analysis of the asuD1, asuD2, and asuD3 mutants. Twenty μL of crude
culture extract of the asuD1 mutant (a), the asuD2 mutant (b), and the asuD3 mutant (c). The
arrows identify the peaks of A1a-A5a, B1a-B4a. The y axis indicates the absorbance abundance
(mAu). Structures of A1a-A5a, B1a-B4a are shown in (d).
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complement the functional activities of each other [21], AsuD2 could represent a new subfamily
of enzymes that deviate from a valid 5-ALA synthase in the evolution. As the 2-oxoamine
synthases catalyze the condensation between the Cα of an amino acid and a CoA thioester, we
suggest that AsuD2 could also perform the intra molecular C-C bond formation between the Cα
and Cε to give a C5N ring structure. A nascent PLP-bound 5-ALA, or possibly the predecarboxylated intermediate, 2-amino-3-oxoadipate, could be carboxyl-activated by the action of
the CoA ligase AsuD3, followed by cyclization catalyzed by AsuD2 (Fig. 5.4). The dual role of
AsuD2 is also supported by the results of the heterologous expression of asuD1-D3 to produce
the C5N unit in the absence of any other candidate cyclase gene in S. lividans. The amide
synthase AsuD1 is responsible for the attachment of the C5N unit to the carboxy-terminus of the
lower chain. As all the assumed intermediates in this process are relatively unstable [20], AsuD1,
D2 and D3 might work together to secure the formation of protoasukamycin.
Similar to other 2-oxoamine synthases, such as FUM8, SPT, and AONS that employ the
amino acids containing bulky side-chain rather than glycine, AsuD2 bears a Ser83 in the position
of the conserved Thr83 of 5-ALA synthase (Fig. 5.1). The distinct role of Ser83 in C5N moiety
formation was confirmed by expression of AsuD2-S83T, which failed to complement the asuD2
mutant but restored the ability of 5-ALA formation in the gtr mutant of S. coelicolor. This point
mutated AsuD2-S83T resembles an authentic 5-ALA synthase, which emerged as a serendipitous
Shemin route to provide sufficient 5-ALA for the growth of gtr mutant. Revealed by the crystal
structure of ALASRc from Rhodobacter capsulatus, the side-chain methyl group of Thr83
interacts with the Cα atom of the PLP-glycine intermediate (3.9 Å) at the active site [118]. In the
presence of this methyl group of Thr83, amino acids other than glycine could not properly
interact with the succinyl-CoA stubstrate, as the bulky side chain will confine the substrate
binding capacity. On contrary, the Ser83 containing enzymes, including FUM8, SPT, and
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AONS, are able to accommodate larger amino acids than glycine, such as alanine and serine.
This not only provides another evidence for the cyclization function of AsuD2 proposed
previously, but also implies the S83T mutation confines the substrate binding pocket, which
facilitate the 5-ALA production but abolish the cyclization function of AsuD2.

Figure 5.4 The proposed C5N moiety biosynthetic pathway and the coexisting C5 pathway.
The dashed arrow indicates the serendipitous Shemin pathway triggered by AsuD2-S83T
mutation. The AsuD2 (green) and AsuD2-S83T (red) are shown in capsules.
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CHAPTER SIX:

POST-ASSEMBLY OXYGENATION OF PROTOASUKAMYCIN
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Results
Growing S. parvulus Tü64 under an 18O2 atmosphere has demonstrated that the hydroxyl
and the epoxide oxygens at the C4 and C5-C6 positions of manumycin A originate from
molecular oxygen, through either a dioxygenase mechanism or a two-step process (Fig. 1.8) [20,
76]. There was no closely related dioxygenase gene detected along the cloned cluster except that
three distantly located genes, the asuE1, asuE2 and asuE3, are likely involved in the oxygenation
reaction(s). AsuE1 is homologous to the p-hydroxybenzoate hydroxylase (PHBH), which
converts p-hydroxybenzoate to form 3,4-dihydroxybenzoate in Pseudomonas aeruginosa (Fig.
6.1) [126]. PHBH is also a bifunctional enzyme which revitalizes an oxidized FADox to FADred
in the presence of NAD(P)H and resume a next round of hydroxylation [127, 128]. Instead to
produce asukamycin, the asuE1 mutant was found to accumulate protoasukamycin C1 and a
series of protoasukamycin related congeners C2-C5 in the fermentation cultural broth based on
LC-MS analysis (Fig. 6.2).

Figure 6.1 Reactions catalyzed by PHBD, PheA1/A2, and LimB.
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AsuE2 is a homolog of the flavin reductase PheA2, which makes a FADred available to its
hydroxylase partner PheA1 in the phenol hydroxylation in Bacillus thermoglucosidasius A7 (Fig.
6.1) [129]. Interestingly, a major amount of the protoasukamycin products C1-C5 and a
considerably lower yield of asukamycin A1 were detected in the asuE2 mutant (Fig. 6.2, 6.3).
This result was rather unexpected and implied that the presence of the AsuE2 FAD reductase is
required to support a full catalytic function of AsuE1, which is distinct to the bifunctional
activity of PHBH.
The asuE3 is highly related to the limB, encoding for a limonene 1, 2-monooxygenase,
which opens the double bond of limonene and introduces an epoxide to form limonene-1, 2epoxide in Rhodococcus erythropolis [130]. Neither asukamycin nor its congeners were detected
in the asuE3 mutant culture. Instead, a significant amount of a bright yellowish compound was
accumulated and revealed a distinct retention time but with a similar UV absorption pattern of
asukamycin A1 by HPLC analysis (Fig. 6.2). A high resolution MS analysis suggested that one
oxygen atom is missing in comparison with the asukamycin A1. 1H-, 13C-, HMBC and HSQC
NMR analysis of the purified compound pointed out that a signature alkene is positioned at C5
(152.5 ppm) and C6 (130.6 ppm) to replace the characteristic epoxide group of asukamycin A1
(Table 6.1). This newly identified compound was assigned as 4-hydroxyprotoasukamycin D1
(Fig. 6.3). Meanwhile, a group of 4-hydroxyprotoasukamycin related congeners D2-D7 also
presented in the fermentation culture based on the LC-MS analysis. D1 was fed into the
fermentation culture of the asuA3 mutant and converted to asukamycin A1, which suggested that
D1 was indeed an intermediate and was further epoxidized by AsuE3 in the final biosynthetic
step for asukamycin (Fig. 6.2).
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Figure 6.2 HPLC analysis of the asuE1-E3 mutants. Twenty μL of crude culture extract of the
asuD1 mutant (a), the asuD2 mutant (b), and the asuD3 mutant (c). Feeding asuA3 mutant with
pure D1 is shown (d). The arrows identify the peaks of A1-A5, B1-B4, C1-C5, D1-D5. The y
axis indicates the absorbance abundance (mAu).
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Table 6.1 NMR connectivities in 4-hydroxyprotoasukamycin (D1). NMR of D1 acquired from 1J- and
n
J-heteronuclear carbon-proton shift correlation methods (HSQC and HMBC).
Position
δC (ppm)
δH (ppm)
C,H-Couplinga
1
180.07
-6-H, 0-NH, 5-H, 3-H
2
140.95
--3
124.57
6.21 (d, J=10.1)
0-NH (w)
4
69.63
-7-H, 3-H, 8-H, 5-H (w), 0-NH (w)
5
152.53
6.93 (dd, J=10.0, 3.1)
6-H, 7-H, 3-H (w)
6
130.64
7.62 (d, J=2.95)
5-H, 3-H, 7-H, 0-NH
7
137.64
5.80 (d, J=15.5)
6-H, 5-H, 3-H, 8-H, 9-H
8
131.12
6.48 (dd, J=14.8, 11.8)
9-H, 10-H
9
138.97
6.66 (dd, J=14.8, 11.2)
7-H, 8-H, 11-H
10
129.35
6.53 (dd, J=15.37, 11.31)
8-H, 11-H
11
141.23
7.07 (dd, J=15.0, 11.6)
10-H, 12-H
12
123.47
6.46 (d, J=15.2)
11-H, 10-H
13
164.94
-14-NH
1’
164.94
-0-NH, 2’-H
2’
123.85
6.51 (d, J=15.2)
3’-H, 4’-H
3’
141.23
7.15 (dd, J=15.0, 11.6)
2’-H, 4’-H, 5’-H
4’
128.53
6.30 (dd, J=14.9, 11.7)
3’-H, 2’-H, 6’-H
5’
140.59
6.63 (dd, J=15.0, 10.9)
3’-H, 6’-H, 7’-H
6’
127.67
6.18 (dd, J=15.2, 10.9)
4’-H, 5’-H
7’
144.84
5.90 (dd, J=15.4, 7.0)
5’-H, 9’/13’-H (w)
8’
40.46
2.08 (m)
6’-H, 7’-H, 9’/13’-H, 10’/12’-H
9’,13’
32.10
1.70 (m), 1.09 (m)
10’/12’-H, 13’/9’-H, 7’-H, 11’-H
10’,12’
25.39
1.26 (m), 1.68 (m)
11’-H, 9’/13’-H, 12’/10’-H
11’
25.60
1.13 (m), 1.63 (m)
10’/12’-H, 9’/13’-H
1’’
2’’
113.57
-3’’
4’’
5’’
NH-14
9.20 (s)
NH-0’
9.17 (s)
a.
Indicated protons show connectivities to the given carbon attributed to 2J-, 3J- or weak 4J-coupling. (w)
weak J-coupling.
b.

Coupling with 8’-H (2.08 ppm) was suppressed.

c. 13

C-NMR and 1H-NMR signals for C1’’, C3’’, C4’’ and C5’’ are undetectable in DMSO-d6.
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Figure 6.3 Structures of C1-C5, D1-D5.

Discussion
Both one-step dioxygenase and two-step monooxygenase mechanisms have been
proposed for the epoxyquinol structure formation of the manumycin compounds [20, 38, 60].
The mutagenesis studies supported that the 4-hydroxyl group is introduced to protoasukamycin
C1 to give a 4-hydroxylprotoasukamycin intermediate D1 through the actions of AsuE1 and
AsuE2, and AsuE3 further introduces an epoxide to replace the C5,6-double bond of D1 to form
asukamycin A1 (Fig. 6.4). The C1 hydroxylation is catalyzed by AsuE1, whose full function
requires the AsuE2 FAD reductase, possibly by using a reductive cofactor NAD(P)H. and the
FAD reduction by AsuE2, possibly using a reductive cofactor NAD(P)H, is required for a full
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function of AsuE1. Since the intermediate D1 was not detected in the asuE2 mutant, it is less
likely that the AsuE3 epoxidation depends on the presence of AsuE2.

Figure 6.4 A comparison of two-step monooxygenase and one-step dioxygenase
mechanisms for the respective asukamycin and vitamin K oxide biosynthesis.
As AsuE3 acts specifically on the cyclohexa-2,5-dienone moiety but not a phenol like
structure, the protoasukamycin 4-hydroxylation to offer a constrained C5,6-double bound is
critical for the epoxidation. Correspondingly, the mmyO, encoding an AsuE3-related epoxidase,
was also found in the deposited methylenomycin A biosynthetic gene cluster of Streptomyces
coelicolor A3(2) [131, 132]. MmyO could have a function in the epoxidation of the desepoxy4,5-didehydromethylenomycin A to form methylenomycin A (Fig. 6.5). Evidently, the upper
chain substituted by an acetyl group and the absence of the C5N moiety have little impact on the
catalytic function of AsuE1,E2,E3 in the epoxyquinol formation as observed for A8 and A1a,
respectively. Both the identified C1 and D1 could serve as proper substrates to address the detail
catalytic aspect of the AsuE1, AsuE2 and AsuE3 enzymes for the further studies.
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Figure 6.5 The proposed function of MmyO in methylenomycin A biosynthesis.
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CHAPTER SEVEN:
A TYPE TWO THIOESTERASE AND OTHER ASUKAMYCIN
BIOSYNTHETIC GENES
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Background of Thioesterases
Based on the functional and structural diversity, the thioesterases in metabolic pathways
are categorized into three groups, type I, type II, and the hotdog-fold thioesterases. Frequently
located at the C-terminus of the polyketide synthase (PKS) or non-ribosomal polypeptide
synthase (NRPS) complexes, type I thioesterase (TEI) acts to release the polyketide or
polypeptide chain from the carrier protein module, either by direct hydration of the thioester
linkage or by a specific intramolecular cyclization [133-135].
Distinct from TEI, the discrete type II thioesterase (TEII) mostly removes the undesirable
acyl or aminoacyl residues from the catalytic enzyme complex caused by a priming or processing
error, as these mischarged enzymes can hold back the entire biosynthetic progress (Fig. 7.1)
[136-139]. Given a high fidelity, an error occurred in any step of the assembly line may cause the
accumulation of the unprocessed molecule-enzyme complex, and severely block the entire
biosynthetic process. TEII plays a surveillance role and revives the mischarged carrier protein
domain, to provide the opportunity for a wanted acyl or aminoacyl unit to bind, as the yields of
the polyketide and polypeptide products were often considerably impaired in the knockout
mutants [138, 140-142]. For example, there is 5% of DKxanthenes accumulated in the TEIIdeficient dkxO mutant compared with the wild type strain of Stigmatella aurantiaca DW4/3-1
[143]. Besides, the truncation of the McyT TEII resulted in a 95% decreased yield of microcystin
in Planktothrix agardhii [144]. In some situation, TEII can also remove a true intermediate from
the intermediate-protein complex. For example, NikP2 TEII tends to discharge β-hydroxyl-His
from the peptidyl carrier protein NikP1 complex in nikkomycins X/I synthesis of Streptomyces
tendae Tü901 [145].
The hotdog-fold thioesterases consist of a long α-helix wrapped around by five or six
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anti-parallel β-sheets, reminiscent of a hotdog. They are mainly known to hydrolyze the CoA or
the carrier protein-tethered acyl substrates for the breakdown of aromatic compounds [146, 147].
Not much is known for the rest of family members.

Figure 7.1 Proposed functions of type II thioesterases (TEII). The correct substrates are
indicated in green; the undesirable intermediate are shown in red.

Results
Thioesterase Affects the Primed CHC
Located near the border of the asu cluster, the asuC15 is closely related to a group of
TEII coding genes found in the polyketide and non-ribosomal peptide biosynthetic gene clusters,
including RifR and SrfD involved in the rifamycin biosynthesis of Amycolatopsis mediterranei
and the surfactin formation of Bacillus subtilis, respectively [140, 148]. Mutation and
biochemical studies indicated that RifR and SrfD discharge the unwanted acyl and aminoacyl
residues from the carrier protein modules in the assembly lines of rifamycin and surfactin,
respectively. Interestingly, the asuC15 mutant produced a normal amount of asukamycin A1, yet
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the yield of the congeners A2-A7 was significantly reduced (Fig. 7.2). This incident is more
evident by measuring up to 10 times higher production of the CHC-primed asukamycins than the
total branched acyl-CoA initiated congeners, unlike a relatively equal distribution observed in
the wild type strain. Since CHC-CoA is not only a building block of asukamycin but can also
form ω-cyclohexyl fatty acids as membrane components in S. nodosus subsp. asukaensis [10],
we analyzed the fatty acid compositions of the asuC15 mutant and the wild type strain by GCMS (Fig. 7.3, Table 7.1). Notably, 16.5% of ω-cyclohexyl-undecanoic acid (cyclohexyl-C17) was
detected in the asuC15 mutant, which is at least five-fold higher than the 3.1% detected in the
wild type strain. Moreover, 1.7% of ω-cyclohexyl-tridecanoic acid (cyclohexyl-C19) fatty acid,
which is undetectable in the wild type strain, was also found.

Figure 7.2 HPLC analysis of the asuC15 mutant and the S. nodosus wild type strain. The
arrows identify the peaks of asukamycin A1 and related metabolites, A2-A5, B1-B4.
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Figure 7.3 Fatty acid profiles generated by GC-MS analysis. The identified fatty acid
derivatives are indicated.
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Table 7.1 Fatty acid composition of S.nodosus wild type strain and the asuC15 mutant.

Fatty acid

Retention
time (min)

Wild
type

AsuC15
mutant

Iso-C14
Normal-C14

10.71
11.04

10.84%
6.99%

2.18%
0.00%

Iso-C15
Anteiso-C15
Normal-C15

11.57
11.66
11.93

6.20%
17.40%
1.52%

2.97%
12.22%
1.13%

Iso-C16
Normal-C16

12.57
12.97

29.68%
9.59%

28.54%
8.38%

Iso-C17
Anteiso-C17
Normal-C17

13.68
13.78
14.14

3.68%
7.76%
0.47%

5.09%
18.08%
0.59%

Iso-C18
Normal-C18

14.92
15.43

0.07%
2.72%

0.58%
2.01%

Cyclohexyl-C17
Cyclohexyl-C19

15.15
18.04

3.06%
0.04%

16.52%
1.71%

Other asu Gene Functions
The AsuC6, a second thioesterase-like protein, belongs to the type of hotdog-fold
thioesterases, which presumably have a role to hydrolyze the thioester bond and release the acyl
intermediate from the PKS enzyme complex [146, 147]. The asuC6 mutant has not yet been
constructed and the precise function of AsuC6 function remains to be clarified. Located between
the asuR group genes and asuE1, asuC1 encodes for a phosphopantetheinyl transferase (PPTase),
which likely primes the apo-ACP by the covalently attaching a 4'-phosphopantetheine moiety of
CoA to give a holo-ACP. Since bacteria always utilizes orthogonal carrier protein recognition as
a strategy to distinguish primary metabolism from secondary metabolism [149], AsuC1 might be
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a dedicated PPTase to prime the asu ACPs, AsuC5, C11 and C12, involved in the lower and
upper chain biosynthesis.
AsuM1, a homolog of numerous antibiotic efflux exporters, could release the synthesized
asukamycin products from the cells. AsuR1-R6, discretely detected at the two border regions of
the cluster, show homology to numerous putative transcriptional regulator genes found in Grampositive bacteria. AsuR1 and AsuR6 are closely related to the LuxR-type transcriptional
regulators [150]. AsuR2 is likely a TetR-like transcriptional regulator [151]. AsuR3 is a putative
integral membrane sensor protein, which could work together with the DNA binding protein
AsuR4 [152]. AsuR5 belongs to the Streptomyces antibiotic regulatory proteins (SARP) [153].
As many antibiotic biosynthesis gene clusters contain one or multiple regulatory genes, AsuR1R6 could have regulatory functions to control the asukamycin biosynthetic gene activities.
AsuH1 is a putative ORF with an unknown function.

Discussion
CHC-CoA is not only the substrate for the PKS AsuC3,C4 in A1 upper chain assembly,
but is also recruited by the FAS complex and assembled into ω-cyclohexyl fatty acids which
account for 3.1% of total cellular fatty acids in S. nodosus subsp. asukaensis [10]. The CHCCoA utilization to form asukamycin A1 and ω-cyclohexyl fatty acids does not occur in a fixed
ratio, as A1 was increased to more than 80% of total asukamycins, while ω-cyclohexyl fatty
acids were kept under 25% of total fatty acids upon feeding excess cyclohexanecarboxylic acid
[10]. For this inconsistent incorporation rate of the CHC substrate to the cellular membrane fatty
acids and the asukamycin products, one explanation is the distinct substrate specificities of FabH
and AsuC3,C4. While FabH prefers the branch chain acyl-CoA starters, AsuC3,C4 favors the
CHC-CoA. A second reason is likely the AsuC15 TEII action to release the tethered
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cyclohexylpropanoate from the FAS-ACP and allow the recruitment of more branched chain
acyl-CoA starters, as the percentage of ω-cyclohexyl fatty acids was increased five-fold in the
asuC15 mutant. The cellular membrane fluidity is probably affected by variations in the content
of ω-cyclohexyl fatty acids via changing the phase transition temperature, as observed for several
thermo-acidophilic bacteria, which may contain up to 90% of ω-cyclohexyl fatty acids [65, 66,
154]. Thus AsuC15 could suppress excessive ω-cyclohexyl fatty acid formation, which helps to
maintain the membrane homeostasis and structural integrity, particularly when the cellular level
of CHC-CoA is rising. Evidently, AsuC15 can also discharge the CHC-acyl intermediate from
AsuC5-ACP to enhance the production of congeners A2-A4, as the asuC15 mutant
predominantly accumulates A1, rather than an equal amount of A1 and A2-A4 observed in the
wild type.
AsuC6, the other thioesterase in the asu cluster, is a hotdog-fold thioesterase. The most
studied hotdog-fold thioesterase, the PaaI from E. coli, hydrolyzes the phenylacetyl-CoA to
liberate CoA from the dead-end products [146]. Similarly, the AsuC6 could be responsible for
A1a-A5a accumulation in the asuD1, D2 and D3 mutants, which are supposed to be tightly
bound to the ACP AsuC11 in the absence of a thioesterase (Fig. 7.4). In fact, as the coronatine
and aminocoumarin biosynthesis involve amide-bond formation between an amine with the free
acid substrates rather than a carrier protein tethered acyl group [155, 156], the similar acylation
of the C5N moiety could require a free carboxylic acid rather than a carrier protein tethered lower
chain intermediate. If so, AsuC6 could release the triene lower polyketide from the carrier
protein in the wild type strain (Fig. 7.4). This seems contradictory to the previous A1a feeding
experiments, which ruled out the lower polyketide intermediate containing free carboxylic group,
[20]. However, the feeding result should be treated with caution, as the non-incorporation could
result from a low permeability of the fed compound.
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Figure 7.4 The proposed function of AsuC6.
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CHAPTER EIGHT:

SUMMARY AND FUTURE PROSPECT
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Summary
Prior to this study, the extensive feeding experiments have been performed to reveal the
biosynthesis of manumycin A and asukamycin. The structure elements of asukamycin, including
a mC7N core, a cyclohexane moiety, and a C5N ring, were proposed to arise from the
corresponding 3,4-AHBA, shikimic acid, and 5-ALA [20, 60, 157]. The lower and upper triene
polyketide chains are likely built up from 3,4-AHBA and CHC-CoA, respectively, through three
steps of classical polyketide condensations. However, the biosynthetic genes involved in 3,4AHBA, CHC-CoA, and triene chain assembly of asukamycin, have yet been uncovered. Until
now, the asuD2 (hemA-asuA) was the only reported gene to work on the C5N moiety
biosynthesis of asukamycin [21]. As the epoxyquinoid structure of the mC7N core is essential for
the biological activities for the manumycin metabolites, the post-assembly oxygenation of
protoasukamycin also attracts massive attention [20, 38, 76].
In this study, the cloning, mutagenic analysis and characterization of the asukamycin
biosynthetic genes have been carried out in S. nodosus subsp. asukaensis (Fig. 8.1). To
summarize, the lower polyketide chain is initiated with 3,4-AHBA, the condensation product of
ASA and DHAP through the catalytic activities of AsuA3 and A1, while the upper chain is
started with the CHC-CoA, which is derived from the shikimate precursor by the action of the
AsuB group enzymes. The 3,4-AHBA is adenylated by AsuA2, loaded on the ArCP AsuC12,
and consecutively condensed with three malonyl extenders by PKS AsuC13,C14 and the
corresponding reducing enzymes, KR AsuC7 and DH AsuC8,C9, to give a trans triene.
Concomitantly, the CHC-CoA is primed by a set of PKSIII AsuC3,C4 and extended with two
additional malonyl-CoA to form a trans triene upper chain. The ACP tethered lower chain
intermediate is linked with the polyketide upper chain by AsuC2, and further attached with a
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Figure 8.1 Proposed asukamycin biosynthetic pathway. The primary metabolite substrates are shown in squares. The ACP and aroyl
carrier protein are in capsules.
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nascent C5N moiety by AsuD1-D3. The resulted protoasukamycin is subsequently introduced a
hydroxy and an epoxide groups by AsuE1/E2 and AsuE3, respectively, to form the final product
asukamycin. Moreover, the AsuC15 type II thioesterase has a function to suppress the formation
of ω-cyclohexyl fatty acid byproducts and likely maintain the homeostasis of the cellular
membrane. Besides, a plausible crosstalk of the biosynthesis between the fatty acids and the
asukamycin metabolites is also proposed.

Future Prospects
The manumycin metabolites hold great promise in pharmaceutical treatments due to their
unique structural moieties. In this work, the genetic and biochemical results set a stage for the
further work to investigate the molecular mechanism of each catalytic step, especially, the
pathway-specific biosynthetic enzymes. This information not only allows us to identify and
study the biosynthetic enzymes for other manumycin metabolites, but also shed lights on the
further bioengineering of the manumycin family compounds.
The Uncharacterized Asukamycin Biosynthetic Genes
Although a majority of the asu genes have been investigated by mutagenesis or
biochemical analysis, the functions of several biosynthetic genes remain elusive. To access these
genes, we can take advantage of the established pART1391 to construct a gene-knockout series
of the pART1391 derivatives, which can be introduced and expressed in S. lividans, following a
similar procedure to the case for pART1361-E3 described in chapter 6. If the corresponding
transformant strains display distinct metabolic profiles compared with that of the wild type, these
genes could be critical for the asukamycin biosynthesis.
Located downstream of asuC13, the asuC14 encodes a protein highly related to PKS
AsuC13, except for a truncated N-terminus and lack of a putative catalytic triad. To address the
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function role of AsuC14, we can create an asuC14 mutant, which might fail to give any
asukamycin product if AsuC14 function together with AsuC13 on the Claisen condensation. As
the iterative type II PKS is frequently paired with its ortholog, a chain length factor (CLF), it is
likely that AsuC14 forms a confined tunnel with AsuC13 to accommodate the growing triene
polyketide. Under this assumption, the asuC14 mutant could generate a new set of asukamycin
derivatives with various lower chains, such as diene, tetraene, or pentene.
AsuC6, a hotdog-fold thioesterase, could also play a role in controlling the lower chain
biosynthesis. This functional activity of AsuC6 can be verified by gene inactivation. If the
majority of asukamycin production was abolished by this mutation, AsuC6 could catalyze the
hydrolysis of the thioester bond to release the lower polyketide from the ACP AsuC11 (Fig. 7.4).
In this case, it is worthwhile to question whether AsuC6 has a substrate preference towards the
triene chain to a premature diketide or triketide intermediate. Therefore, a series of di-, tri-, and
tretraketides can be synthesized and linked to the CoA analog, N-acetyl cysteamine (SNAC), for
a further in vitro enzymatic evaluation, where a significantly higher catalytic activity on the
tretraketide than the di- or triketide would suggest the participation of AsuC6 in the chain length
control.
The only set of the PKS reducing enzymes in the asu cluster, the ketoreductase AsuC7
and the dehydratases AsuC8,C9, were proposed to function in the compilation of the triene
polyketides. The asuC7 or asuC8,C9 mutants likely fail to produce asukamycin and congeners.
These mutants may only accumulate 3,4-AHBA rather than the asukamycin derivatives
containing trioxo- or trihydroxy-polyketide chains, as the downstream type II PKS AsuC13,C14
may reject the 3-oxodiketide or 3-hydroxydiketide intermediates, which seize the asu ACPs and
block the downstream synthesis. Besides, the plausible involvement of AsuC7 and AsuC8,C9 in
the upper chain biosynthesis can also be justified by checking the presence of E1 and E3/E4
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metabolites accumulated in the mutants. If so, the absence of these reducing enzymes should
ultimately add to the production of cyclohexyl fatty acids, or even form the 3,4-AHBA initiated
fatty acids. To date, there is no reported 3,4-AHBA initiated fatty acids, which might be detected
in the asuC7 mutant, asuC8,C9 mutant, or the previously constructed asuA2 and asuC11C12
mutants.
Besides these structural biosynthetic genes, the resistant genes have yet been clarified in
the asu cluster. Functional expression of the pART1391 in S. lividans indicated that these cloned
asu genes are sufficient to convey the self-immunity of asukamycin. A major facilitator
superfamily (MFS) transporter, AsuM1, has been found and proposed to serve as an antibiotic
efflux transporter to free the nascent asukamycin products from the cells. The asuM1 can be
inactivated in pART1361 and pART1361-E3 to give the pART1361-M1 and pART1361-E3M1,
respectively, which were separately introduced into S. lividans. Presumably, the transformant
carrying a pART1361-M1 is lethal, or displays severe growth retardation, while the pART1361E3M1 may produce 4-hydroxyprotoasukamycins, D1-D5, as a quinol structure of the premature
D1-D5, unlike the expoxyquinol core of asukamycin, exhibits no cytotoxicity.
Mutation study indicated that the AsuC15 TEII suppresses the formation of the ωcyclohexyl fatty acids and likely maintains the homeostasis of the cellular membrane. We
assumed that AsuC15 releases the tethered 3-cyclohexylpropanoate from the FAS-ACP, which
allows the recruitment of the branched chain acyl-CoA starters. To confirm this novel activity,
the asuC15 can be cloned into the shuttle vector pIJ622 under the control of the constitutive
ermE* promoter to generate pART1401, which is further expressed in S. lividans. The resulted
transformant of S. lividans/pART1401 can be fed with cyclohexanecarboxylic acid and analyzed
the cellular level of ω-cyclohexyl fatty acids, which is expected to be lower than that in the S.
lividans carrying a control empty vector. Moreover, we can perform an enzymatic assay using
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the recombinant AsuC15 to hydrolyze the 3-cyclohexylpropanyl-ACP, which could be
synthesized from a 3-cyclohexylpropanyl-SNAC and a FAS-ACP by the malonyl-CoA:ACP
transacylase SgFabD of Streptomyces glaucescens [158]. AsuC15 should display higher catalytic
activity towards the 3-cyclohexylpropanyl-ACP than a butyryl-ACP or 4-methylpentanyl-ACP,
the ubiquitous intermediates for Streptomyces fatty acid biosynthesis.
The Biosynthesis of Other Manumycin Metabolites
Despite that the biosynthetic genes involved in the C5N moiety and CHC-CoA
assemblage are closely positioned and appears to be co-transcribed, many functionally related
asu genes are not organized in an apparent order in the cluster (Fig. 2.1). For instance, the key
genes asuA1 and asuA3 performing the 3,4-AHBA formation are alienated by eight unrelated
ORFs and belong to two separated transcription units, whereas the equivalent griI and griH
position side by side and possibly share the same transcript engaged in the grixazone production
in S. griseus [59]. This implies that the acquired asukamycin biosynthesis has evolved through
multiple horizontal gene transfer events and possibly an extensive genomic rearrangement in S.
nodosus, which could be further confirmed by comparison with other closely related manumycin
biosynthetic gene clusters.
As the majority of other manumycin metabolites share an mC7N core as well as a C5N
moiety, we can probe with the asuA, asuD, and asuE group genes to find the corresponding
biosynthetic genes, such as the ones for manumycin A and colabomycin from S. parvulus Tü64
and Streptomyces griseoflavus Tü2880, respectively. Notably, S. griseoflavus Tü2880 produces
solely colabomycins that possess a trans tetraene lower polyketide, while S. nodosus
accumulates asukamycins and congeners containing an identical lower triene chain. This
structural disparity of triene and tetraene suggests that these two strains employ distinct enzyme
systems to control the length of the lower polyketide chain (Fig. 8.2). The colabomycin producer
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might develop the specified type II PKS components to set up a larger binding pocket than that
of the AsuC13,C14, to accommodate a tetraene polyketide chain. In addition, a hotdog-fold
thioesterase could play a key role to release the ACP tethered tetraene rather than triene for the
colabomycin lower chain assembly.

Figure 8.2 Structures of manumycin metabolites from S. nodosus asukaensis, S. parvulus
Tü64, and S. griseoflavus Tü2880.
The most diverse building block of the manumycin metabolites is the upper polyketide
chain. Instead of a CHC-primed triene chain, manumycin A-C opens the upper tetraketide
assembly using an ACP-tethered butyryl substrate, likely a fully-reduced fatty acid intermediate
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resulted from the action of FabH in S. parvulus (Fig. 8.2). Butyryl-CoA is also employed as a
building starter of several polyketide products, including R1128 [159], murayaquinone [160],
FD-594 [161], and sulfurmycinone [162]. After the initiation process, the nascent diketide
intermediates of manumycin A and B are further extended through three and two runs of
condensations using methylmalonyl-ACPs, respectively. Alternatively, manumycin C differs
from manumycin A at the third extender unit, a malonyl-ACP rather than the methylmalonylACP. This promiscuity could be resulted from three aspects: 1). a limited supply of the
methylmalonyl substrate; 2). a low stringency of the polyketide condensation enzyme; 3). a low
specificity of the downstream amide synthase, an AsuC2 homolog. To test the first possibility, an
extra amount of methylmalonate and malonate can be add to the culture of S. parvulus, and an
increasing production ratio of manumycin A against B and C could specify the consequence due
to a shortage of methylmalonyl substrate. Since the condensation enzymes involved in
asukamycin upper chain formation has not been fully addressed, it is worthwhile to target other
PKS genes in the manumycin gene cluster. Besides, we should be aware of the amide synthase, a
asuC2 homolog, which could process a premature triketide to form manumycin C. Furthermore,
the saturated configuration on the C5,C6 position of the manumycin A upper chain is expected to
arise from the action of an additional reductase, which could function independently or
immediately after the formation of the diketide with a fixed stereospecificity.

Synthesis of the Unnatural Asukamycin Metabolite
To expand the diversity of the metabolites, one approach is to supplement the synthetic
precursors to fermentation cultures. For example, the alicyclic carboxylates with a variable ring
size has been fed and resulted in the production of the novel asukamycin analogs, containing
various cyclic ring structures to substitute the cyclohexane moiety in S. nodosus [10]. However,
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this could be ineffective due to the competition between these synthetic precursors and the
natural CHC-CoA. In this study, the constructed asuB1 mutant, which failed to form the CHCCoA, provides a better platform for these feeding approaches mentioned above than the wild
type strain.
Moreover, the constructed asuA3 and asuA1 mutants with the 3,4-AHBA deficiency can
be used to synthesize many asukamycin analogs by feeding 3,4-AHBA analogs, such as 3,5AHBA, 3-aminobenzoic acid (Fig. 8.3). These analogs bear a distinct core structure to replace
the native mC7N moiety, which could lead to novel biological activities, as the epoxyquinoid
feature was proposed to convey the antimicrobial activities for manumycin metabolites. Besides,
these feeding experiments can also justify the specificity of the AsuE1-E3 oxygenases, in which
the oxidized core points toward that these oxygenases are capable of processing the
corresponding 3,4-AHBA derivative.
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Figure 8.3 Confirmed or postulated asukamycin analogs obtained by feeding the asuA3 or
asuA1 mutants with diverse aromatic precursor. The solid arrows indicate previously
reported or partially confirmed feeding results, while the dashed arrows show the possible
derivatives.
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CHAPTER NINE:

MATERIALS AND METHODS
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Bacterial Strains and Chemicals
S. nodosus subsp. asukaensis ATCC 29757 was obtained from the American Type
Culture Collection. S. lividans K4-114 was kindly provided by Dr. C. Khosla. E. coli strains
were obtained from the John Innes Center (Norwich, UK). Media and chemicals were purchased
from Difco, Sigma Aldrich and EMD. All chemicals and solvents were of reagent or HPLC
grade and were used without further purification unless otherwise mentioned.

Fermentation and Analysis of the Asukamycin Metabolites
Fermentation and Feeding Experiments
Wild type and mutant strains of S. nodosus subsp. asukaensis were cultivated with freeze
storage spores in 25 mL YMG medium in 250 mL baffled flasks with coil on a rotary shaker at
250 rpm and 28°C for 2-3 days [20, 110, 163]. The presence of the asukamycin products was
confirmed by the bioassay against the growth of Staphylococcus aureus. S. lividans K4-114
recombinant strains were cultured in 25 mL R5 or MS medium for 4-5 days [163]. If required,
the media were supplemented with the selective antibiotics at following the concentrations:
apramycin (50 µg/mL); kanamycin (20 µg/mL); spectinomycin (50 µg/mL). Feeding
experiments with 3,4-AHBA (100 µg/mL) and 4-hydroxyprotoasukamycin (20 µg/mL) were
conducted by adding these compounds to one day-old cultures and harvesting one day later.
HPLC and LC-MS Analysis
Fermented cultures were mixed thoroughly with an equal volume of ethyl acetate.
Separated by centrifugation, the ethyl acetate layer was collected and evaporated to near dryness.
The crude extract was dissolved in an equal volume of methanol and analyzed using a P680
HPLC system (Dionex, Sunnyvale, CA USA) and an XTerra RP18 column (4.6 X 250 mm,
Waters) at a flow rate of 0.5 mL/min at 25°C. Twenty µL of crude extract were injected,
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equilibrated with 65% solvent B (acetonitrile with 0.1% formic acid) in solvent A (water with
0.1% formic acid) for 5 min, developed with a gradient of 65-90% solvent B in solvent A for 20
min and washed with 90% solvent B in solvent A for 10 min. To analyze the asuD1-D3 mutants,
a gradient of 50-70% solvent B in solvent A was applied instead. The extraction and HPLC
analysis of 3,4-AHBA followed the described protocol [59].
High resolution MS and LC-MS analyses were carried out on a 6210-TOF LCMS system
(Agilent Technologies Inc., Santa Clara, CA USA), in which the LC was performed using a
XDB C18 (4.6 X 50 mm, 1.8 micron particle size) high throughput column (Agilent technologies,
Inc.) with the same elution program as the HPLC analysis mentioned above. The exact masses of
the identified compounds are listed in Table 9.1.
Fatty Acid Analysis
The mycelia of the fermentation cultures were collected, washed three times with 10%
glycerol and mixed with 3 mL MeOH:CHCl3 (2:1) in a glass homogenizer. The mixture was
separated by centrifugation, and the supernatant was further rinsed three times with 1 mL of
water. The organic layer was extracted, hydrolyzed and the methyl esters of the fatty acids were
prepared [164, 165]. The GC-MS analysis was conducted on a Trace Gas Chromatograph
(Thermo Quest Inc. Schaumburg, IL, USA) using a 30 m x 0.25 mm DB-225 column with a 0.15
m film thickness (J&W Scientific, Folsom, CA). The flow rate of the carrier gas ultrapure helium
was 1.5 ml/min and the GC program was as follows: 60°C for 1 min; 15°C/min to 200°C;
5°C/min to 260°C and hold for 10min. The peak areas were recorded by XCalibur-Qual Browser
software (Thermo Quest Inc. Schaumburg, IL, USA). The signals of the fatty acid methyl esters
were identified by comparison with authentic samples purchased from Sigma, NuCheck Prep.

90

Table 9.1 Exact mass of asukamycin and its derivatives.
Formula

Calculated
Mass

Observed
Mass

Mass Error Upper Chain
(ppm)
Fragment

A1

C31H34N2O7

546.2366

546.2360

1.19

189.13

A2

C28H30N2O7

506.2053

506.2062

1.78

149.09

A3, A4

C29H32N2O7

520.2210

520.2228

3.62

163.11

A5

C30H34N2O7

534.2366

534.2377

2.05

177.13

A6, A7

C31H36N2O7

548.2523

548.2530

1.36

191.14

B1

C31H36N2O7

548.2523

548.2528

0.91

189.13

B2

C28H32N2O7

508.2210

508.2229

3.74

149.10

B3, B4

C29H34N2O7

522.2366

522.2382

3.06

163.11

B5

C30H36N2O7

536.2523

536.2517

1.02

177.13

C1

C31H34N2O5

514.2468

514.2477

1.73

189.13

C2

C28H30N2O5

474.2155

474.2163

1.68

149.10

C3, C4

C29H32N2O5

488.2311

488.2317

1.15

163.11

C5

C30H34N2O5

502.2468

502.2477

1.77

177.13

D1

C31H34N2O6

530.2417

530.2422

0.90

189.13

D2

C29H32N2O6

504.2260

504.2254

1.25

149.10

D3, D4

C28H30N2O6

490.2104

490.2110

1.34

163.11

D5

C30H34N2O6

518.2417

518.2411

1.06

177.13

A8

C20H20N2O7

400.1271

400.1289

4.73

---

B8

C20H22N2O7

402.1427

402.1444

4.19

---

C8

C20H20N2O5

368.1372

368.1394

6.02

---

A1a

C26H29NO6

451.1995

451.2010

3.44

189.13

A2a

C23H25NO6

411.1682

411.1657

6.13

149.09

A3a,A4a

C24H27NO6

425.1838

425.1804

8.13

163.11

A5a

C25H29NO6

439.1995

439.1990

1.09

177.12

B1a

C26H31NO6

453.2151

453.2171

4.43

189.13

B2a

C23H27NO6

413.1838

413.1801

8.93

149.09

B3a, B4a

C24H29NO6

427.1995

427.1956

9.19

163.10

B5a

C25H31NO6

441.2151

441.2120

7.05

177.12
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Purification and NMR Analysis of D1 and B8
A reliable yield of the novel intermediate 4-hydroxyprotoasukamycin D1 was obtained in
S. lividans K4-114 carrying pART1361E3, which was generated from pART1361 with the λ-Red
PCR strategy by replacing asuE3 with a spectinomycin resistance gene. S. lividans K4114/pART1361E3 was inoculated into 500 mL MS medium in 2-liter flasks with a coil and
fermented on a rotary shaker at 250 rpm and 28°C for 4-5 days. One liter of harvested culture
was extracted three times with an equal volume of ethyl acetate, and the combined ethyl acetate
extract was dried, concentrated and purified on a silica gel column (100-200 mesh), eluting with
dichloromethane/methanol (100:3). The compound D1 fraction was collected and further
purified by semi-preparative C18 reverse-phase HPLC (Dionex), eluting with 75-85% solvent C
(methanol with 0.1% formic acid) in solvent A, to give 20 mg of pure compound D1. Its 1HNMR, 13C-NMR, HSQC and HMBC spectra were recorded in DMSO-d6 on a Varian System 700
spectrometer (Table 6.1).
To purify the B8, the asuC2 mutant was inoculated into 50 mL YMG medium in 250 mL
flasks with coils and fermented at 250 rpm and 28°C for 3 days. One liter of harvested culture
was extracted three times with an equal volume of ethyl acetate. The combined ethyl acetate
extract was dried, concentrated and purified on a silica gel column (100-200 mesh), eluting with
dichloromethane/methanol (90:10). The compound B8 fraction was further purified by semipreparative C18 reverse-phase HPLC (Dionex), eluting with 35-50% solvent C in solvent A, and
2 mg of pure compound B8 was obtained. Its 1H- and 13C-NMR spectra were recorded in
DMSO-d6 on a Varian System 700 spectrometer (Table 4.1).

Genomic Library and Mutant Construction
Molecular biology procedures and DNA manipulations were carried out according to
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standard protocols. The cosmid genomic library of S. nodosus subsp. asukaensis was constructed
by cloning the Sau3AI partially digested genomic DNA into pOJ446, an E. coli-Streptomyces
shuttle vector. Ligation mixtures were further packaged with the Gigapack III Gold Packaging
kit (Stratagene) and transfected into E. coli SURE strain (Stratagene). Two 32P-labled DNA
probes, the chcA and asuD2 genes, were used for screening the constructed cosmid library.
To construct mutants by antibiotic resistance gene insertion, the target gene-containing
DNA fragment was cloned into the BamHI site of the pGM160 vector [163]. The internal coding
region with or without the junction region were deleted or replaced with either the 1.4 kb
apramycin resistance gene or the 0.8 kb kanamycin resistance gene from pOJ446 or pBluescript,
respectively (Fig. 9.1) [163]. The truncated plasmid clones were delivered by polyethylene
glycol-based transformation into S. nodosus subsp. asukaensis, and integrated into the
chromosome forced by incubating the transformants at 39°C with continuing selection for
thiostrepton resistance. One or two rounds of streaking at 39°C in the absence of thiostrepton
allowed the identification of thiostrepton-sensitive strains, in which the targeted genes were
replaced with the antibiotic resistance gene. The resulting recombinants were further confirmed
by Southern hybridization analysis (Fig. 9.1), except for the mutant asuA2, which was verified
by chromosome walking and genomic sequencing.
To construct the asuE1 mutant, the 1.5 kb upstream and downstream regions, including
100 bp of asuE1, were amplified by PCR and tandem cloned in the pHGF9050 vector. The four
oligonucleotide primers used, AsuE1-1 to -4, are listed in Table 9.2. The resulting pART1334
was transformed into E. coli ET12567/pUZ8002 and conjugated with S. nodocus subsp.
asukaensis wild type [163]. The apramycin resistant recombinants resulting from the
homologous recombination between the plasmid and the wild type S. nodosus were further
selected, subcultured in MS liquid medium for 1-2 rounds, and screened for apramycin sensitive
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recombinants derived from a second crossover event. The double crossover recombinant was
confirmed by Southern hybridization analysis (Fig. 9.1).
Table 9.2 Oligonucleotide primers used for the mutant constructions and λ-Red
recombinations.
Primers

Sequence from 5’ to 3’

AsuE1-1

CCCAAGCTTCGAAGACCCGTGGCGTGAGCC

AsuE1-2

CCCAGATCTCCGCGCGCACAGCAGCGC

AsuE1-3

CCCAGATCTCCGGCGGTGAAGGGCGCGCAC

AsuE1-4

CCCCTCGAGACCTGATGGAGGGGTCCAGTA

AsuRED-4

GGTCCGGAAGCGGCCTGCGGAGCGCCCTGCGGGGCGGCTCTAGA
GATATCATTCCGGGGATCCGTCGACC

AsuRED-6

AGAACCACGGCTGGACCGAGGGCTGACACCCCCGGGGCGTATCC
GGCCGTTGTAGGCTGGAGCTGCTTC

AsuREDE3F

AGTCGTCAGCCTGCCCTACCACCACCCGTTCATGGTGGCCTCGCG
GGCCATTCCGGGGATCCGTCGACC

AsuREDE3R

AGCCGACGATCGTGCTGCGCCGGTCGATCAGCTCGGCCAGGGCCT
TGCGTGTAGGCTGGAGCTGCTTC

S83TF

AAGGATCCGGCGGCACCCGCAACATCGGTGGCACCAA

S83TR
GGGATGGAGGTGGTGAAGATGAAG
* The underlined regions indicate the DNA sequence matching pART1361.
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Figure 9.1 Southern blots of thirteen constructed mutants. Hybridization probes and
anticipated restriction digestion patterns are indicated.
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fig. cont’d
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fig. cont’d

98

fig. cont’d
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Reassembly and Heterologous Expression of the Cloned asu Cluster
The E. coli BW25113/pIJ790 was cultivated in LB medium supplemented with 25 µg/mL
chloramphenicol plus 10 mM L-arabinose at 28°C [89]. When the OD600 reaches 0.6, the E. coli
cells were harvested, washed with ice-cold 10% glycerol for three times, concentrated and
stocked in the ice-cold GYT (10% glycerol; 0.125% yeast extract; 0.25% tryptone). The cosmid
clones 2B9 and 10D6 were linearized by restriction digestion with SpeI and EcoRI, respectively,
equally mixed and introduced into E. coli BW25113/pIJ790 by electroporation. The cells were
then added to 1 mL SOC [89], recovered at 37°C for 3 hours, and plated out onto LB agar with
100 µg/mL apramycin. For the negative control, the linearized 2B9 and 10D6 were transformed
separately by the same procedure. The recombinant clone was confirmed by matching the
anticipated EcoRI digestion pattern and named pART1361 (Fig. 2.2). Intergeneric conjugation of
the recombinant cosmids from E. coli to S. lividans K4-114 followed the established protocol
[163].
To construct pART1391, a 1.5 kb DNA fragment from pIJ778 was PCR-amplified using
primers AsuRED-4 and -6 (Table 9.2) to carry a spectinomycin resistance gene cassette plus two
50-bp nucleotides, designed to be identical to the boundaries of the targeted region on
pART1361 (Fig. 2.3) [89]. To obtain the recombinant strain, the gel-purified PCR fragment was
introduced into E. coli BW25113/pART1361/pIJ790 by electroporation, and the transformants
were screened for spectinomycin resistance. The deletion in the resulting clone was confirmed by
matching up to the expected EcoRI digestion pattern and verified by PCR. The pART1361E3
construction followed the same strategy as described above but using primers AsuRED-E3F and
-E3R (Table 9.2).
To insert the point mutation that modifies the TCC (Ser) codon into ACC (Thr) in the
asuD2 gene, the internal fragment containing the BamHI-KpnI sites was PCR-amplified using
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primers S83TF and S83TR (Table 9.2). The BamHI-KpnI-cleaved fragment was then used to
replace the corresponding region in the pALS3 plasmid. The further steps were identical with the
pALS4 construction [21].
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